MGT003, Gene Therapy Trial for LCA OPTIRPE65                                        
 
Page 2 of 67 
MGT003, Protocol version 8.0 11 June 2018  
Table of Contents  
1. Administrative information  ................................................................................................................... 7 
1.1 Compliance  ................................................................................................................................... 7 
1.2 Sponsor  ......................................................................................................................................... 7 
1.3 Structured trial summary  .............................................................................................................. 8 
1.4 Roles and responsibilities .............................................................................................................. 9 
1.4.1  Protocol contributors  ................................................................................................................ 9 
1.4.2  Independent Data Monitoring Committee  ............................................................................. 10 
2 Trial Diagram  ....................................................................................................................................... 11 
3 Abbreviations  ...................................................................................................................................... 12 
4 Introducti on ........................................................................................................................................ 15 
4.1 Background and Rationale  .......................................................................................................... 15 
4.1.1  Background  ............................................................................................................................. 15 
4.1.2  Preclinical Data  ........................................................................................................................ 16 
4.1.3 Rationale  .................................................................................................................................  16 
4.1.4  Risk/Benefit  ............................................................................................................................. 17 
4.1.5  Assessment and Management of Risk  .................................................................................... 17 
4.1.5.1 Risk of immune responses to AAV capsid proteins or expressed RPE65 protein  ....................... 17 
4.1.5.2 Risk of vector transmission to other organs  ............................................................................... 17 
4.1.5.3 Risks of ins ertional mutagenesis and oncogenesis  ..................................................................... 18 
4.1.5.4 Risk of germline transmission  ..................................................................................................... 18 
4.1.5.5Risk of surgical adverse effects  .................................................................................................... 18 
4.1.5.6Risk of adverse effects of short -term corticosteroids  .................................................................  19 
4.1.5.7Risks of investigations performed during assess ment and follow up  ......................................... 19 
4.1.5.8 Conclusion on the risk -benefit ratio  ........................................................................................... 19 
4.1.6  Explanation for Choice of Comparators  .................................................................................. 20 
4.2 Objectives ........................................................................................................................................ 20 
4.2.1  Primary Objective  .................................................................................................................... 20 
4.2.2  Secondary Objective  ............................................................................................................... 20 
4.3 Trial Design  ...................................................................................................................................... 20 
MGT003, Gene Therapy Trial for LCA OPTIRPE65                                        
 
Page 3 of 67 
MGT003, Protocol version 8.0 11 June 2018  
4.3.1  Overall Design  ......................................................................................................................... 20 
4.3.1.1 Separate longer term follow up study  ........................................................................................ 21 
4.3.2  IMP administration Review and Dose Escalation Criteria and Process  .................................. 21 
4.3.2.1 Dose escalation criteria and Dose Limiting Events  ..................................................................... 22 
4.3.2.2  Dosing process  ........................................................................................................................ 22 
4.3.2.2.1 Cohort 1  ................................................................................................................................... 22 
4.3.2.2.2 Cohort 2  ................................................................................................................................... 23 
4.3.2.2.3 Cohort 3  ................................................................................................................................... 23 
4.3.2.2.4 Additional considerations  ........................................................................................................ 23 
4.3.2.2.5 Confirmatory safety phase  ....................................................................................................... 25 
5 Methods  .............................................................................................................................................. 25 
5.1 Site Selection  ............................................................................................................................... 25 
5.1.1  Stud y Setting  ........................................................................................................................... 25 
5.1.2  Site/Investigator Eligibility Criteria  ......................................................................................... 25 
5.1.2.1  Principal Investigator’s (PI) Qualifications and Agreements  ................................................... 26 
5.1.2.2  Resourcing at site  .................................................................................................................... 26 
5.2 Site approval and activation  ....................................................................................................... 26 
5.3 Participants  .................................................................................................................................  27 
5.3.1  Eligibility Criteria  ..................................................................................................................... 27 
5.3.1.1  Participant selection  ............................................................................................................... 27 
5.3.1.2  Participant Inclusion Criteria ................................................................................................... 27 
5.3.1.3  Participant Exclusion Criteria .................................................................................................. 28 
5.3.1.4  Eligibility Criteria for Individuals Performing the Interventions  ............................................. 28 
5.3.1.5  Co-enrolment Guidance  .......................................................................................................... 28 
5.3.1.6  Screening Procedures  ............................................................................................................. 28 
5.3.1.6.1  Informed Consent Procedure  .............................................................................................. 29 
5.3.1.6.2  Screening Period  ................................................................................................................. 29 
5.3.1.6.3  Enrolment  ........................................................................................................................... 30 
5.4 Interventions  ................................................................................................................................... 30 
5.4.1  Products  .................................................................................................................................. 30 
5.4.1.1  Name and Description of Investigational Medicinal Product(s)  ............................................. 30 
MGT003, Gene Therapy Trial for LCA OPTIRPE65                                        
 
Page 4 of 67 
MGT003, Protocol version 8.0 11 June 2018  
5.4.1.2  ATIMPs Classified as Genetically Modified Organisms  ........................................................... 31 
5.4.1.3  Source of ATIMPs  .................................................................................................................... 31 
5.4.1.4  Preparation and Labelling of the Investigational Medicinal Product  .................................  31 
5.4.1.5  Description and Justification of Route of Administration and Dose  ....................................... 32 
5.4.1.6  Name and Description of Each Non -Investigational Medicinal Drug (NIMP)  ......................... 33 
5.4.2 Protocol defined clinical schedule  .......................................................................................... 34 
5.4.2.1  Baseline Assessments  ............................................................................................................. 34 
5.4.2.2  ATIMP administration Procedures  .......................................................................................... 36 
5.4.2.2.1 Preoperative procedure  ........................................................................................................... 36 
5.4.2.2.2 Operative procedure  ................................................................................................................ 37 
5.4.2.3  Subsequent Assessments  ........................................................................................................ 38 
5.4.2.4  Laboratory Procedures  ............................................................................................................ 39 
5.4.3  Dispensing  ............................................................................................................................... 40 
5.4.3.1  Receipt and Storage of the Investigational Medicinal Product  .............................................. 40 
5.4.4  Dosages  ................................................................................................................................... 40 
5.4.4.1  Dosage s and dosage modifications  ......................................................................................... 40 
5.4.5  Accountability  ......................................................................................................................... 40 
5.4.6  Compliance and Adherence  .................................................................................................... 41 
5.4.7  Concomitant Care  ................................................................................................................... 41 
5.4.8  Overdose of Trial Medication  .................................................................................................  41 
5.4.9  Protocol Discontinuation  ........................................................................................................ 42 
5.4.9.1  Subject Withdrawal  ................................................................................................................. 42 
5.4.9.2  Trial Stopping Rules  ................................................................................................................. 42 
5.5 Outcomes  .................................................................................................................................... 42 
5.5.1  Primary Outcomes  .................................................................................................................. 42 
5.5.2  Secondary Outcomes  .............................................................................................................. 43 
5.6 Trial Assessments  ........................................................................................................................ 44 
5.6.1  Early Stopping of Follow -up .................................................................................................... 46 
5.6.2  Loss to Follow -up .................................................................................................................... 46 
5.6.3 Trial Closure  ............................................................................................................................ 46 
5.6.4  Passive/Long Term Follow -Up After the End of the Trial  ........................................................ 46 
MGT003, Gene Therapy Trial for LCA OPTIRPE65                                        
 
Page 5 of 67 
MGT003, Protocol version 8.0 11 June 2018  
5.7 Sample Size  ..................................................................................................................................... 46 
5.8 Recruitment and Retention  ............................................................................................................ 46 
5.8.1  Recruitment  ............................................................................................................................ 46 
5.8.2  Retention .................................................................................................................................  47 
5.9 Assignment of Intervention  ............................................................................................................ 47 
5.9.1  Allocation  ................................................................................................................................ 47 
5.10  Data Co llection, Management and Analysis  ............................................................................... 47 
5.10.1  Data Collection,Management and Entry  ................................................................................. 47 
5.10.3  Non -Adherence and Non -Retention  ....................................................................................... 48 
5.10.4  Statistical Methods  ................................................................................................................. 48 
5.10.4.1  Statistical Analysis Plan  ....................................................................................................... 48 
5.10.4.2  Statistical Methods – Primary Outcome Analysis  ............................................................... 48 
5.10.4.3  Statistical Methods - Secondary Outcome Analysis  ............................................................ 49 
5.10.4.4  Statistical Methods – Health Economic Analysis  ................................................................ 49 
5.11  Data Monitoring  .......................................................................................................................... 50 
5.11.1  Independent Data Monitoring Committee (IDMC)  .................................................................  50 
5.11.2  Interim Analyses  ...................................................................................................................... 50 
5.11.3  Data Monitoring for Harm  ...................................................................................................... 50 
5.11.3.1  Safety reporting  .................................................................................................................. 50 
5.11.3.2  Other Notifiable Adverse Events  ......................................................................................... 51 
5.11.3.3  Procedures to follow in the event of female participants becoming pregnant  .................. 52 
5.11.3.4  Procedures to follow in the event of the partners of male participants becoming pregnant
 52 
5.11.3.5  Investigator responsibilities relating to safety reporting  .................................................... 52 
5.11.3.5.1  Seriousness assessment  .................................................................................................. 53 
5.11.3.5.2  Severity or grading of Adverse Events  ............................................................................ 53 
5.11.3.5.3  Causality  .......................................................................................................................... 53 
5.11.3.5.4  Expectedness  .......................................................................................................... 54 
5.11.3.6  Notifications  ........................................................................................................................ 55 
5.11.3.6.1  Notifications by the Investigator to EMAS  ...................................................................... 55 
5.11.3.6.2  Reporting Urgent Safety Measures  ................................................................................. 56 
MGT003, Gene Therapy Trial for LCA OPTIRPE65                                        
 
Page 6 of 67 
MGT003, Protocol version 8.0 11 June 2018  
5.11.3.6.3  EMAS responsibilities  ...................................................................................................... 56 
5.11.3.6.4  Reporting SUSARs in International Trials  ........................................................................ 56 
5.11.3.6.5  Annual Progress Reports  .................................................................................................  57 
5.11.4  Quality Assurance and Control  ................................................................................................... 57 
5.11.4.1  Risk Assessment  .................................................................................................................. 57 
5.11.4.2 Clinical Monitoring  .................................................................................................................... 57 
5.11.4.3.1  Direct access to participant records  ............................................................................... 57 
5.11.4.4  Trial Oversight  ..................................................................................................................... 57 
5.11.4.4.1  Clinical Management Team  ............................................................................................ 58 
5.11.4.4.2  Independent Data Monitoring Committee  ..................................................................... 58 
5.11.4.4.3  Trial Sponsor  ................................................................................................................... 58 
6 Ethics and Dissemination  .................................................................................................................... 58 
6.1 Research Ethics Approval  ............................................................................................................ 58 
6.2 Competent Authority Approvals  .................................................................................................  58 
6.3 Other Approvals  .......................................................................................................................... 59 
6.4 Protocol Amendments  ................................................................................................................ 59 
6.5 Consent or Assent  ....................................................................................................................... 59 
6.6 Confidentiality  ............................................................................................................................. 60 
6.7 Declaration of Interests  .............................................................................................................. 61 
6.8 Indemnity  .................................................................................................................................... 61 
6.9 Finance  ........................................................................................................................................ 61 
6.10  Archiving  ..................................................................................................................................... 61 
6.10.1  Archiving of Essential Trial Documentation Relating to Traceability  ...................................... 61 
6.10.2  Archiving of Other Essential Trial Documentation  .................................................................. 62 
6.11  Access to Data  ............................................................................................................................. 63 
6.12  Ancillary and Post -Trial Care  ....................................................................................................... 63 
6.13  Publication Policy  ........................................................................................................................ 63 
6.13.1  Trial Results  ......................................................................................................................... 63 
7 Ancillary Studies  .................................................................................................................................. 63 
8 Revision History  .................................................................................................................................. 63 
9 References  .......................................................................................................................................... 65 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 7 of 67 
  
1. Administrative information  
This document was constructed using the MeiraGTx UK II Ltd . Protocol template . It describes the  Gene 
Therapy T rial for LCA OPTI RPE65  trial, sponsored and co -ordinated b y MeiraGTx UK II Ltd .  
It provides information about procedures for entering participants into the trial, and provides sufficient 
detail to enable: an understanding of the background, rationale, objectives, trial  population, 
intervention, methods, statistical analyses, ethical considerations, dissemination plans and 
administration of the trial; replication of key aspects of trial methods and conduct; and appraisal of the 
trial’s scientific and ethical rigour from the time of ethics approval through to dissemination of the 
results. The protocol should not be used as an aide -memoire o r guide for ATIMP administration to  other 
patients . Every care has been taken in drafting this protocol, but corrections or amendments may be 
necessary. These will be circulated to registered investigators in the trial.  
MeiraGTx UK II Ltd . supports the co mmitment that its trials adhere to the SPIRIT guidelines. As such, t he 
protocol  template is based on an adaptation of the Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) 2012 Statement for protocols of clinical trials  (Chan et al. 2013a) . The 
SPIRIT Statement Explanation and Elaboration document  (Chan et al.  2013b)  can be referred to , or a 
member of MeiraGTx UK II Ltd . Clinical Operations team can be contacted for further detail about 
specific items.  
1.1 Compliance  
The trial will be conducted in compliance with the approved protocol  and with the following:  
• Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  
MeiraGTx UK II Ltd . will be informed of any possible serious breach of compliance as soon as it is 
identified, so that the requirement t o report the breach can be fulfilled within the relevant applicable 
timelines specified in each country in which the study is being conducted.  
For the purposes of reporting,  a ‘serious breach’ is one that is likely to affect to a significant degree:  
• The safety or physical or mental integrity of the participants in the trial, or  
• The scientific value of the trial.  
1.2 Sponsor  
MeiraGTx UK II Ltd ., 92 Britannia Walk, London N1 7NQ is the study sponsor.   
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 8 of 67 
  
1.3 Structured trial summary  
 
Primary Registry and T rial 
Identifying Number  Clinical trials.gov  ([STUDY_ID_REMOVED])  
 
Secondary Identifying Numbers  EudraCT : 2015 -003418 -25 
Sponsor protocol number : MGT003  
Source of Monetary or Material 
Support  Medical Research Council  (MRC grant reference: 
MR/M015815/1)  
MeiraGT x UK II Ltd. 
Sponsor  MeiraGTx UK II Ltd . 
Contact for Public Queries  ocularinfo@meiragtx.com  
Contact for Scientific Queries  James Bainbridge MA PhD FRCOphth  
Professor of Retinal Studies  
UCL Institute of Ophthalmology  
11-43 Bath Street  
London EC1V 9EL  
Tel: 020 7608 6889  
Fax: 020 7608 6991  
Email: j.bainbridge@ucl.ac.uk  
Public Title  Gene Therapy Trial for LCA OPTIRPE65  
Scientific Title  An Open -label, Multi -Centre , Phase I/II Dose Escalation Trial 
of an Adeno -Associated Virus Vector (AAV2/5 -OPTIRPE65 ) for 
Gene Therapy of Adults and Children with Retinal Dystrophy 
associated with Defects in RPE65  (LCA2)  
Countries of Recruitment  United Kingdom, United States of America  
Health Condit ion(s) or Problem(s) 
Studied  Retinal dystrophy associated with defects in RPE65  
Intervention(s)  Open label, non -randomised, dose -escalation (low dose at 
1.0 x1011 vg/mL; intermediate dose at 3.0 x1011 vg/mL; high 
dose at 1.0 x1012 vg/mL), phase I/II study, by subretinal 
administration of AAV2/5 -OPTIRPE65  in up to 27  participants 
with LCA caused by mutations in RPE65 .  
Key Inclusion and Exclusion Criteria  Key Inclusion Criteria:  
• Aged 3 years or older  
• Early-onset severe retinal dystrophy consistent with RPE65  
deficiency  
• Homozygous or compound heterozygous missense or null 
mutations in RPE65  
• Functional or structural evidence of photoreceptor 
preservation  
• Able to undertake age -appropriate clinical as sessments  
• Willing to give consent for the use of blood and blood 
components collected throughout the trial for the 
investigation of immune response to ATIMP  
 
Key Exclusion Criteria:  
• Females who are pregnant or breastfeeding  
• Contraindications for transient immune -suppression (i.e. 
history of diabetes mellitus, gastric or duodenal ulceration, 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 9 of 67 
  
hiatus hernia,  uncontrolled  gastro -oesophageal reflux in the 
past or are using non -steroidal anti- inflammatory drugs on a 
regular basis at the time of screening)  
Have participated in another research study involving an 
investigational therapy  for ocular disease  within the last 6 
months .  
• Have had intraocular surgery within 6 months of screening.  
• Have an ocular or systemic disorder that may  preclude 
subretinal surgery and/or interfere with interpretation of 
the study results  
Study Type  Phase I/II, o pen-label, non-randomised, 2 centre, d ose 
escalation in adults and children with retinal dystrophy 
associated with defects in RPE65  
Date of First Enrolment  April  2016  
Target Sample Size  Up to 27  participants  
Primary Outcome(s)  The primary outcome is safety of subretinal administration of  
AAV2/5 -OPTIRPE65 .  
 
Safety is defined as the absence of ATIMP related : 
• reduction in  visual acuity by 15 ETDRS letters or more  
• severe unresponsive inflammation  
• infective endophthalmitis  
• ocular malignancy  
• Grade III or above non -ocular SUSAR Safety will be 
assessed for 6  months after the intervention.  
Key Secondary Outcomes  The secondary outcomes are measures of the efficacy of the 
intervention, which will be performed on an individual 
participant basis and will be descriptive in nature.  
 
1) Any improvement in visual function from baseline that is 
greater that the test- retes t variation for that test and is 
sustained for at least two consecutive assessments.  
 
2) Any improvement in retinal function from pre intervention  
that is greater than the test- retest variation and measurable 
by electroretinography (ERG) . 
 
3) Quality of li fe measures  
1.4 Roles and responsibilities  
These membership lists are correct at the time of writing; please see terms of reference documentation 
in the TMF for current lists.  
1.4.1  Protocol contributors  
Name  Affiliation  Role  
James Bainbridge  University 
College London  CI - Protocol development including surgical 
considerations  
Michel Michaelides  University 
College London  Protocol development including clinical assessments  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 10 of 67 
  
Stuart Naylor  MeiraGT x UK 
Ltd. Protocol development  
Julie Bakobaki  MeiraGT x UK 
Ltd. Protocol development and co -ordination  
Victoria McCudden  UCL CCTU  Clinical Project Manager  
Simon Skene  UCL CCTU  Principal Statistician  
Neruban Kumaran  University 
College London  Protocol development  
Praseeda Thaikalloor  MeiraGTx UK 
Ltd Protocol  development and co -ordination  
1.4.2 Independent Data M onitoring Committee  
Name  Affiliation  Role and responsibilities  
Professor Hatice Nida 
Sen National 
Institutes of 
Health  Independent Chair , Clinical Professor of 
Ophthalmology  
Graeme MacLennan  University of 
Aberdeen  Independent statistician  
Emma Morris  UCL Institute of 
Immunity and 
Transplantation  Independent member , Professor of Clinical Cell and 
Gene Therapy  
Andrew Baker  University of 
Edinburgh  BHF Professor of Translational Cardiovascular Sciences  
 
 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 11 of 67 
  
2 Trial Diagram  
 
 
 
 
 
 
 
 

MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 12 of 67 
  
3 Abbreviations  
AAV  Adeno -Associated 
Virus  
Ad Adenovirus  
AE Adverse Event  
AF Autofluorescence  
AO Adaptive Optics  
AR Adverse Reaction  
ATIMP  Advanced Therapy 
Investigational 
Medicinal Product  
bps Basepairs  
BGL65p  hRPE65  promoter 
fragment that i s less 
efficient than the 
NA65p promoter  
CA Competent Authority  
CAI Codon Adaptation 
Index  
cDNA  complementary 
Deoxyribonucleic Acid  
CLIA  Clinical Laboratory 
Improvement 
Amendments  
CI Chief Investigator  
CMT  Clinical Management 
Team  
CMV  Cytomegalovirus  
CNS Central nervous 
system  
CRF Case Report Form  
CRO  Contract Research 
Organization  
CTA Clinical Trial 
Authorisation  
CTCAE  Common Terminology 
Criteria for Adverse 
Events  
CTIMP  Clinical Trial of 
Investigational 
Medicinal Product  
DAPI  4',6-diamidino -2-
phenylindole  
DLE Dose -limiting event  
DNA  Deoxyribonucleic acid  
DSUR  Development Safety 
Update Report  
EC European Commission  
eGFP  enhanced green 
fluorescent protein  ELISA  Enzyme -linked 
Immunosorbent Assay  
ELISPOT  Enzyme -linked 
ImmunoSpot Assay  
EMA  European Medicines  
Agency  
EOSRDs  early -onset severe 
retinal dystrophies  
EQ-5D-5L EuroQOL Quality of 
Life 5 dimension 5 
level  
ERG Electroretinography  
ETDRS  Early Treatment 
Diabetic Retinopathy 
Study  
EU European Union  
EUCTD  European Clinical Trials 
Directive  
EudraCT  European Clinical Trials 
Database  
EudraVIGILANCE  European database for 
Pharmacovigilance  
FAF Fundus 
Autofluorescence  
FDA (US) Food and Drug 
Administration  
FWA  Federal Wide 
Assurance  
GCP Good Clinical Practice  
GFP Green Fluorescent 
Protein  
GLP Good Laboratory 
Practice  
GMO  Genetically Modified 
Organism  
GMP  Good Manufacturing 
Practice  
GMSC  Genetic Modification 
Safety Committee  
GTAC  Gene Therapy Advisory 
Committee  
H&E  haematoxylin and 
eosin  
HEK293T  human embryonic 
kidney epithelial cell 
line 
hRPE65  human retinal pigment 
epithelium -specific 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 13 of 67 
  
protein 65 (all -trans -
retinyl isomerase)  
HSE Health and Safety 
Executive  
HTA Human Tissue 
Authority  
H2B histone H2B  
IB Investigator Brochure  
ICF Informed Consent 
Form  
ICH International 
Conference on 
Harmonisation  
IDMC  Independent Data 
Monitoring Committee  
IMP Investigational 
Medicinal Product  
IMPD  Investigational 
Medicinal Product 
Dossier  
IND Investigational New 
Drug  
IRB Institutional Review 
Board  
ISF Investigator Site File  
ISRCTN  International Standard 
Randomised Trial 
Number  
ITRs Inverted terminal 
repeats  
ITT Intention to Treat  
IV (or iv)  Intravenously  
IVI Impact of Visual 
Impairment  
KEC Kellog g Eye Centre  
LCA Leber  congenital 
amaurosis  
LCA2  Retina l dystrophy 
associated with defects 
in RPE65  
LREC  Local Research Ethics 
Committee  
MA Marketing 
authorisation  
Main REC  Main Research Ethics 
Committee  
mGMP  Manner -of-good 
manufacturing practice  MHRA  Medicines and 
Healthcare p roducts 
Regulatory Agency  
MRI Magnetic Resonance 
Imaging  
MTD  Maximum Tolerated 
Dose  
mRNA  Messenger RNA  
NA65p  Optimised hRPE65  
promoter  
NHS R&D  National Health Service 
Research & 
Development  
NIH National Institutes of 
Health  
NIMP  Non Investigational 
Medicinal Product  
NZW  New Zealand White  
OBA  Office of Biotechnology 
Activities  
OCT Optical Coherence 
Tomography  
ONL  Outer nuclear layer  
PCT Polymerase Chain 
Reaction  
PERG  Pattern 
Electroretinogram  
PHI Protected Health 
Information  
PI Principal Investigator  
PIS Participant Information 
Sheet  
QA Quality Assurance  
QALY  Quality Adjusted Life 
Year  
QC Quality Control  
qds  quarter die sumendus 
(four times a day)  
QOL  Quality of Life  
QMMP  Quality Management 
and Monitoring Plan  
qPCR  Quantitative 
Polymerase Chain 
Reaction  
QP Qualified Person for 
release of CTIMP  
qPCR  Quantitative 
polymerase chain 
reaction  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 14 of 67 
  
rAAV  Recombinant adeno 
associated virus  
rAAV2/2  recombin ant adeno -
associated virus 
serotype 2  
R&D  Research and 
Development  
REC Research Ethics 
Committee  
RG Research grade  
RNA  Ribonucleic acid  
RPE Retinal Pigment 
Epithelium  
RPE65  retinal pigment 
epithelium -specific 
protein 65 (all- trans -
retinyl isomerase)  
rt-PCR reverse 
transcription - polymer
ase chain reaction  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR Serious Adverse 
Reaction  
SD standard deviation  
SDV Source D ata 
Verification  
SOP Standard Operating 
Procedure  
SmPC Summary of Product 
Characteristics  
SSA Site Specific Approval  
SSAR  Suspected Serious 
Adverse Reaction  
SUSAR  Suspected Unexpected 
Serious Adverse 
Reaction  
SV40  Simian virus 40  
TMF  Trial Master File  
ToR Terms of Reference  
tRNA  Transfer ribonucleic 
acid 
UAR  Unexpected Adverse 
Reaction  
UCL University College 
London  
UCLH  University College 
London Hospital  
UK United Kingdom  US United States of 
America  
vg Viral Genomes  
WGTU  Wolfson Gene Therapy 
Unit  
WT Wild type  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 15 of 67 
  
4 Introduction  
4.1 Background and Rationale  
4.1.1  Background  
Inherited retinal degenerations cause sight impairment in approximately 1 in 3000 people in the 
Western world. There are currently no effective treatments. Leber congenital amaurosis (LCA) is a 
severe, early -onset form of inherited retinal degeneration inv olving both rod and cone photoreceptors 
(Perrault et al . 1999; Koenekoop, 2004). LCA is caused by mutations in one of at least 19 different genes 
(see https://sph.uth.edu/retnet ). Mutations in RPE65 , which is expr essed in the retinal pigment 
epithelium (RPE), are responsible in 3  to 16 % of people affected. The RPE65  gene encodes a  65-kDa 
retinal pigment epithelium (RPE) -specific protein that is required for the conversion of vitamin A to 11 -
cis-retinal by the RPE and is essential for the regeneratio n of the rod visual pigment ( Hamel et al. 1993; 
Redmond et al . 2008 ). Mice and dogs that are homozygous for RPE65  null mutations have abnormally 
low levels of 11 -cis-retinal, resulting in very poor vision and depressed light - and dark -adapted 
electroretinogram responses  (Ekesten et al . 2001; Dekomien et al . 2003 ). Children with RPE65  mutations 
lack rod function from birth; residual cone function is typically extinguished by early adulthood 
(Marlhens et al . 1997; Cremers et al. 2002 ). 
Proof -of-principle for RPE65  gene replacement therapy has been demonstrated using recombinant 
adeno -associated virus serotype 2 (rAAV2/2) vectors in animal models ( Acland et al . 2001; Acland et al. 
2005;  Jacobson et al . 2006; Le Meur et al . 200 7; Bennicelli et al . 2008 ) of the condition and in 3 previous 
clinical trials (Bainbridge et al . 2008;  Maguire et al . 2008;  Cideciyan et al . 2008).  In these 3 studies, 
adults and children as young as 6 years of age, were administered AAV vectors by sub -retinal 
administration at viral doses ranging from 1.5x1010 to 1x1012. Although vector administration was 
generally well- tolerated, a minority o f participants who were adminis tered 1012 viral genomes 
developed transient intraocular inflammation and immune re sponses to AAV indicating dose -limiting 
toxicity (Bainbridge et al . 2015). In all instances , intraocular inflammation resolved following more 
extended administration of corticosteroid treatment.  
In all 3 clinical trials, subsets of participants benefitted with improved visual function to varying extents 
during the first year. However, longer- term follow -up demonstrated that progressive degeneration 
continued unabated, and the maximal improvements in retinal sensitivity were not maintained 
(Cideciyan et al . 2013;  Bainbridge et al . 2015). Additional pre -clinical studies have shown that 
endogenous expression of RPE65  in humans is greater than in the animal models, and support the 
hypothesis that continued degeneration reflects suboptimal RPE65  expression in the human retina 
(Bainbridge et al. 2015).  
To increase the availability of RPE65  for affected humans we have developed a new optimized AAV 
vector. Having identified in our previous clinical trial the maximal tolerated AAV2/2 vector dose, we  
have optimized the therapeutic vector to drive more efficient transgene expression. We have achieved 
this by optimization of the construct and the Kozak sequence, inclusion of an exogenous intron, and 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 16 of 67 
  
codon optimization. We will use an AAV2/5 vector to de liver the construct because we have determined 
that AAV2/5 vectors are more effective than AAV2/2 vectors for gene therapy in Rpe65 -deficient mice. 
The aim of this trial is to determine the safety of this new optimised AAV2/5 vector in humans and to 
explor e its potential efficacy.  
4.1.2  Preclinical Data   
Our new optimised vector, AAV2/5 -OPTIRPE65 , provides 300 -fold greater efficacy in animal models 
compared with that used in our previous trial.  
The toxicity of a single dose of AAV2/5 -OPTIRPE65 administere d as a subretinal injection has been 
evaluated in mice and rabbits.   Long -term (9 -month) overexpression of RPE65  protein in the mouse RPE 
did not result in gross toxicity, as determined by clinical observations of health and behaviour or by 
increased mortality, or in ocular toxicity, as determined by functional and structural assessments of 
retinal health (Study RPE65 -02/01).   In 8-week single dose studies in mice (Study  RPE65 -02/02) and 
rabbits (Study  RPE65 -02/04), subretinal administration of AAV2/5 -OPTIRPE65 did not result in local 
adverse effects on retinal structure or function.   No overt systemic effects on health, as assessed by 
appearance or behaviour of the animals, or by macroscopic examination of the major organs post -
mortem, were observed.   Low l evel dissemination of vector to the liver, adrenal glands, and draining 
lymph nodes was detected in mice, and low level dissemination of vector to the liver and tissues of the 
optic tract was detected in rabbits .  This low level dissemination of vector did  not result in pathological 
changes.   Subretinal administration of AAV2/ -OPTIRPE65 in an Rpe65 -deficient mouse strain did not 
result in adverse local or systemic effects (Study  RPE65 -02/03).  
No immune responses against the RPE65  protein were detected in a 4 -week, single dose study of 
bilateral subretinal injection in the Rpe65 -deficient ( Rpe65−/−) mouse Study  (RPE65 -02/03).  There were 
some immune responses against the vector capsid in this study and in the 8 -week single dose toxicity 
and biodistribution stu dies of AAV2/5 -OPTIRPE65 in mice (Study RPE65 -02/02) and rabbits (Study 
RPE65 -02/04), as would be expected after administration of AAV vector.   These were only detectable 
using the neutralising antibody assay.   Anti-AAV5 immune responses were not more pron ounced in the 
Rpe65 -deficient ( Rpe65−/−) mouse compared with WT mice, and did not correlate with any changes in 
any of the other assessments.    
4.1.3  Rationale  
Inherited defects in the gene encoding RPE65  cause night blindness and progressive loss of sight in 
children. There is currently no approved treatment available. In previous clinical trials we and others 
have shown that subretinal administration of recombinant AAV2/2 vector s containing the cDNA for 
human RPE65  is generally well- tolerated and can improve low -luminance vision (night vision) in affected 
children and young adults  (Bainbridge et al . 2008; Maguire et al . 2008; Cideciyan et al . 2008; Bainbridge 
et al . 2015). However, the efficacy of the intervention in humans is lower than that measured in mice 
and dogs with a similar condition. We hypothesise that higher efficacy can be achieved in affected 
humans by improving the efficiency of expression of RPE65  through optimisation of the vector 
construc t. The purpose of this trial is to determine whether administration o f a new version of the 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 17 of 67 
  
vector ( AAV2/5 -OPTRPE65 ), which has been optimised for efficiency of both transduction and RPE65  
protein production, is safe and can result in greater efficacy.  
4.1.4  Risk/Benefit  
A gene therapy trial in human volunteers should not put the participants at disproportionate risk and for 
this reason should be restricted to individuals with serious disorders where effective treatments are not 
available . Children with  RPE65  mutations lack rod function and night vision from  birth; residual cone 
function and daylight vision is severely impaired by early adulthood. There is no established  treatment. 
Although younger individuals in particular stand to benefit from gene supp lementation therapy by virtue 
of their visual plasticity to accommodate an improvement in  retinal function, we anticipate that people 
of a range of ages may benefit  – as seen in the three aforementioned Phase 1 clinical trials . To de fine 
this range we will include  participants of various ages in the trial; once an acceptable safety  profile  has 
been established in adults, we will include children. We will enhance the safety of the proposed 
approach by restricting transgene expression to the target tissue by virtue of rAAV vector tropism and 
the promoter sequence used, and by restricting the intervention to only one eye of each participant.  The 
risk of adverse effects on foveal function will be further minimised by  preferentially  targeting the vector 
surgically to the extrafoveal retina.  
4.1.5  Assessment and Management of Risk  
The MHRA risk categorisation to participant safety in relation to the ATIMP is Type C (i.e. markedly 
higher than the risk of standard medical care). General risk management will include the detailed review 
of participant s, appropriate intervals between ATIMP administration to successive participants, the dose 
escalation plan, and limiting the risks to children by initially demonstrating an acceptable safety profile 
in adults. In addition,  the schedule of participants’ assessments has been designed to identify the short-
term and the long- term risks. Details of specific risks and their management strategies are outlined 
below.  
4.1.5.1 Risk of immune responses to AAV capsid proteins or expres sed RPE65 
protein  
There is a risk that inflammation will occur following intra- ocular administration of rAAV in participants. 
The risk of inflammation is likely to be highest during the early postoperative period after ATIMP 
administration, before vector capsids are degraded. The risk of inflammation during this period will be 
minimised by pre - and post -operative prophylactic administration of topical and systemic 
corticosteroids. In our first clinical trial of gene therapy, intra- ocular delivery of an AAV 2/2 vector was 
followed by transient intraocular inflammation in 3 of 12 particip ants. In this current protocol , 
intraocular administration of an AAV2/5 has been well tolerated in the majority of participants to 
date.  A minority of participants developed an episode of  intraocular inflammation involving the 
posterior segment, which responded to  further administration of systemic corticosteroids . 
4.1.5.2 Risk of vector transmission to other organs  
Biodistribution studies suggest that following subretinal inje ction of rAAV, there may be anterograde 
and trans -synaptic transport of small amounts of vector genome from the retina to central visual 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 18 of 67 
  
structures (Stieger et al . 2008). This is likely to result from inadvertent transduction of retinal ganglion 
cells following reflux of vector into the vitreous. Since only tiny amounts of vector are likely to reach the 
brain, the possibility of transgene expression causing toxicity in the brain is likely to be very low.  
4.1.5.3 Risks of insertional mutagenesis and oncogene sis 
The possibility of oncogenic events due to vector -mediated insertional mutagenesis cannot be excluded 
with certainty, but available evidence suggests it to be unlikely given that (i) rAAV vector genomes 
integrate into host chromosomes at a very low fre quency (Nowrouzi et al . 2012), (ii) a relatively low 
number of rAAV particles will be administered, and (iii) the eye predominantly contains non -dividing 
cells and consequently ocular tumours are very rare. Furthermore, oncogenesis has not been reported 
following injection of rAAV into thousands of rodent eyes. Even when we injected AAV vectors into a 
large number of tumour -prone p53-/- mice, we did not observe  malignant transformation of retinal cells 
(Balaggan et al . 2012).   
In the highly unlikely event that an intraocular tumour does arise in a participant , comprehensive 
monitoring procedures will enable early detection and thus prompt and appropriate management.  
4.1.5.4 Risk of germline transmission  
The risk of inadvertent germline transmission is very small. In a number of studies using a variety of 
animal models involving various routes of administration, including intraocular injection, inadvertent 
germline transmission by rAAV vectors has not been  detected. Similarly, we detected no vector 
genomes in semen of participants in our previous retinal gene therapy clinical trial (Bainbridge et al . 
2008). Howev er, in a P hase I clinical trial  where rAAV2 was used to deliver factor IX in participants with 
haemophilia B, vector sequences have been detected in semen samples, though not sperm, from 6 (of 7) 
participants for a short period after vector delivery (Manno et al . 2006). Although this indicates there 
may be some potential for inadvertent germline tran smission following the systemic delivery of high 
doses of vector suspension, the possibility of such an event following the microsurgical delivery of tiny 
amounts of vector to intraocular compartments is considered to be remote. Participants who are fertile 
and sexually active will be requested to  use double -barrier contraception for at least 12 months 
following ATIMP administration .  
4.1.5. 5 Risk of surgical adverse effects  
The risk of significant surgical adverse effects is similar to the standard surgical care for other common 
forms of vitreo -retinal disorders.  Only highly experienced surgeons will perform the procedure to limit 
the risk of surgical adverse events. These complications can normally be treated effectively by 
medication or further surgery and rarely result in a permanent effect on eyesight. The risk of permanent 
severe visual loss  from vitrectomy surgery  is approximately 1 in 1000. We have identified no significant 
surgical adverse effects in any of the 12 participants in our previous clinic al trial performed using the 
same surgical procedure.  
Delivery of vector suspension to the subretinal space will be performed following a standard surgical 
vitrectomy. This will involve a 3 -port pars plana vitrectomy followed by injection of vector suspen sion 
using a fine cannula through small retinotomies, resulting in a transient retinal detachment. Previous 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 19 of 67 
  
gene therapy clinical trials have shown that the bleb of subretinal vector suspension will resolve 
spontaneously over the course of the first 24 to 48 hours postoperatively as the fluid is absorbed by the 
underlying retinal pigment epithelium.  
The aim of the intervention is to improve and/or to protect photoreceptor cell function. Previous trials 
have identified a risk of retinal thinning at the fove a, which is the site of greatest cone density, following 
subfoveal vector delivery. Although such thinning is not clearly associated with an adverse effect on 
foveal function in the short -term, we cannot exclude the possibility in the longer -term, and for this 
reason we aim to exclude the fovea from the area of vector delivery in the proposed trial.  
Potential complications of surgery specifically include persistence of the subretinal vector bleb, the 
development of retinal tears, and persistent postoperati ve intraocular inflammation. We will minimise 
any risk to overall visual function by leaving the contralateral fellow eye untreated. Retinal detachment 
caused by persistent vector bleb or intraoperative retinal tear is expected to occur in fewer than 1 in 100 
cases and can be effectively managed in the majority of participants by retinopexy with or without 
appropriate intraocular tamponade. Persistent intraocular inflammation will be managed by topical 
corticosteroid therapy with systemic steroids where ind icated.  
Vitrectomy surgery is a standard technique, commonly performed for a wide range of indications. 
Injection of fluids under the retina is less commonly performed but injection of Hartmann’s solution 
(similar in composition to lactated Ringer's solut ion) is a standard step in surgery for macular 
degeneration.  
4.1.5.6  Risk of adverse effects of short -term corticosteroids  
Candidates will be screened to ensure there are no contra -indications for transient immune suppression 
by corticosteroids; in particu lar, a history of uncontrolled hypertension, diabetes  mellitus , tuberculosis,  
renal impairment, osteoporosis, gastric ulceration, severe affective disorder and immunocompromise d 
status . The possibility of steroid -induced adverse effects will be monitored r egularly. In particular, blood 
pressure and blood glucose will be measured  on Baseline, Day 1, Week 1, Week 2 and Week 4 , as will 
renal function and liver function (at baseline and 1 day, 7 days, 2 weeks and 4 weeks  and 6 weeks after 
surgery ).  
4.1.5.7  Risks of investigations performed during assessment and follow up  
The majority of investigations are non -invasive routine clinical tests and present no significant risk. 
Venepuncture causes temporary discomfort, occasionally bruising/swelling and rarely in fection at the 
site of puncture.  
4.1.5.8 Conclusion on the risk -benefit ratio  
In conclusion, the clinical benefit of delivery of the RPE65  gene to the retinal epithelium was 
demonstrated in the clinical trial conducted with the first generation product (A AV2/2 -hRPE65).   Based 
on the specific modifications to that product (both regulatory elements that control gene expression, 
and sequences to enhance translation), it is hypothesised that AAV2/5 -OPTIRPE65 will produce higher 
levels of RPE65 protein than AAV 2/2-hRPE65, leading to greater improvements in visual function in 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 20 of 67 
  
patients with LCA2. The investigators judge the scientific value of the trial and potential for individual 
participants to benefit outweigh the risks associated with the intervention . 
4.1.6 Explanation for C hoice of C omparators  
There is no currently approved treatment for retinal dystrophy caused by mutations in RPE65 , thus 
there are no comparators in this study. The contralateral fellow eye will be left untreated to minimize 
the risk to visu al function and may also serve as a control.  
4.2 Objectives  
4.2.1  Primary Objective  
The primary research objective is to assess the safety of a new optimised virus vector for RPE gene 
replacement in the retina. Safety is  defined as  an ATIMP related : 
• Reduction in visual acuity by 15  ETDRS letters  or more  
• Severe unresponsive inflammation  (defined below)  
• Infective endophthalmitis)  
• Ocular malignancy  
• Grade III or above non -ocular  SUSAR  (See Section  5.11.3 ) 
Classification of severe unresponsive inflammation will be according to the SUN (standardisation of 
uveitis nomenclature) Working Group grading system  (Am J Ophtha lmol. 2005 Sep;140(3):50916.) i.e  
• anterior chamber cells 3+ (26 -50 cells in a field size of 1mm x 1 -mm slit -beam), or  
• anterior chamber flare 3+ (marked, iris and lens  details hazy) or  
• vitreous haze 3+ (Ophthalmology 1985; 92:467 -71)  
that fail to improve by 2 steps (or to g rade 0) during a 6 week period.  
4.2.2  Secondary Objective  
The secondary research objective is to determine whether a new optimised virus vector for RPE65 gene 
replacement in the retina is effective at improving sight  in terms of both visual and retinal function , and 
quality of life . 
4.3 Trial Design  
4.3.1  Overal l Design  
This is an  open -label phase I/II dose -escalation trial to determine the safety and efficacy of a single 
subretinal administration of the ATIMP in participants with RPE65 -related retinal dystrophy.  
In the dose escalation phase, up to 18 adult pa rticipants  will be administered one of 3 different doses of 
vector in cohorts of 3 participants at a time, using a 3+3 design. Based on toxicity data, the IDMC will 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 21 of 67 
  
make a recommendation on the dose to administer to the next cohort of 3 participants. The IDM C may 
recommend   additional participants be treated at a given dose before deciding how to proceed.  
Adults are defined as participants aged 16+ in the UK and aged 18+ in the US.  
Up to 9 children  or adults  (aged 3 or older)  will then be included once an acceptable safety profile has 
been  established in adults . The IDMC will agree  the maximum tolerated dose in adults before 
recommending administering up to this  dose in children.  
Safety and efficacy will be assessed by clinical examination and special inves tigations according to the 
schedule in section 5 .6 of the protocol  for 6 months following the intervention.  
4.3.1.1 Separate longer term follow up study  
Participants will subsequently be invited to enrol in a separate 5 -year follow -up study where they will  be 
assessed for safety up to 60 months following ATIMP administration.  The duration of long -term follow -
up is therefore consistent with the recommendations of the current CHMP Guideline on Follow -up of 
Patient s Administered with Gene Therapy Medicinal Products (EMEA/CHMP/GTWP/60436/2007) of 22 
October 2009, where it is stated that, for viral vectors without integration, latency or reactivation 
potential, a brief clinical history and sample testing should be performed pre -treatment, at 3, 6 and 12 
months a fter treatment, and then yearly thereafter for a minimum of 5 years (and, if non -clinical tests or 
evidence from other clinical trials using identical vectors or modifications of vectors indicate a potential 
for integration or late re -activation, the monit oring should be extended to continue yearly after those 5 
years until data indicate that there is no longer any risk to be followed ). Further, although the FDA 
Guidance for Industry: Gene Therapy Clinical Trials –  Observing Subjects for Delayed Adverse Eve nts 
(November 2006) recommends a standard 15 -year period of follow -up, it is also noted that a shorter 
period of follow up may be possible if the vector does not integrate and has no potential for latency and 
reactivation.  The follow up study will be a non -intervention study designed to  collect data on longer 
term safety and efficacy at the equivalent of 9, 12, 18, 24, 36, 48 and 60 months following ATIMP 
administration; as such, participants in both studies will be followed up more frequently than 
recommended in the guidance, as additional assessments following ATIMP administration are included 
in the initial study (at weeks 1, 2, 4 , 6 and 9 ) and in the long- term follow up study (at months 9 and 18). 
The follow up study will be supported by a different s ource of funding, will have a separate protocol, 
participant  information and consent processes, and will be submitted for separate ethical review. 
Participants in the current study will be encouraged to join the follow up study as part of their ongoing 
clinical review, but there will be no obligation on their part to do so.  It is acknowledged that despite 
encouragement participants may choose not to participate in the long -term follow -up study; however, 
in this motivated population, where individuals are c losely and regularly monitored by their specialist, 
this number is expected to be very small. Moreover, we anticipate that participants are more likely to 
join a long- term study at 6 months than at 2 years  following intervention . 
4.3.2  IMP administration  Review and Dose Escalation Criteria and Process  
Up to 18  adult parti cipants (as defined in  Section 4.3.1)  will be administered 1 of 3 doses according to 
the dose -escalation criteria:  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 22 of 67 
  
1) low dose   1mL at 1.0 x1011 vg/mL  
2) intermediate dose  1mL at 3.0 x1011 vg/mL  
3) high dose   1mL at 1. 0x1012 vg/mL  
Once a maximal tolerated dose is established, up to a further 9 participants aged 3 or above will continue 
to be administered vector  up to the highest dose observed to be well tolerated in adults . 
4.3.2.1 Dose escalation criteria  and Dose Limiting Events  
Dose escalation will be undertaken in adults,  based on an escalation rule  around Dose -Limiting Events  
(DLEs). An IDMC will review data from a minimum of 9 weeks of follow up from each cohort of 3 
participants , before recommending the next dose to be assessed in a further cohort of participants . 
A DLE is defined as  any of the below occurring during the 9 weeks following administration , at least 
possibly related to the ATIMP, not surgery alone : 
• Reduction  in visu al acuity by 15 ETDRS  letters  or more  
• Severe unresponsive inflammation  
• Infective endophthalmitis  
• Ocular malignancy or  
• Grade III or above non -ocular SUSAR  (see section 5.11.3)  
Severe unresponsive inflammation will be defined according to the Standardisation of Uveitis 
Nomenclature (SUN) Working Group grading system  (Jabs et Al.  2005) i.e.  
• anterior chamber cells 3+ (26 -50 cells in a field size of 1mm x 1 -mm slit -beam), or  
• anter ior chamber flare 3+ (marked, iris and lens  details hazy) , or  
• vitreous haze 3+ (Ophthalmology 1985; 92:467 -71) 
that fails to improve by 2 steps (or to grade 0) during a 9 -week  period.  
Review of safety data will be undertaken by the IDMC prior to each dose  escalation. Children will be 
included at up to the highest safe vector dose recommended by the IDMC , once a safety profile has 
been established in adult participants .   
4.3.2.2  Dosing process  
4.3.2.2.1 Cohort 1  
Vector will first be administered at the lowest dose to 1 adult participant only . This participant will be  
monitor ed for signs of toxicity for a period of 9 weeks.  If there is no  DLE as defined above  after a minimum 
of 9 weeks , vector  will continue to be administered  at the same dose to 2  further adult participants . In 
the event of a DLE in the first adult in the cohort, a discussion will be held with the IDMC  to agree a 
plan of action for administering the ATIMP to further adults.  The IDMC will review the data collec ted on 
this cohort of participants  up to  9 weeks following vector administration to the 3rd participant .  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 23 of 67 
  
4.3.2.2.2 Cohort 2  
In the event that there  is no DLE in any participant, the IDMC will recommend administering  vector at the 
intermediate dose level to a single adult participant.  If there is no dose -limiting toxicity  after a minimum 
of 9 weeks , vector  will continue to be administered  at the same dose to 2 further adult participants. In 
the event of a DLE in the first adult in the cohort, a discussion will be held with the IDMC  to agree a 
plan of action for administering the ATIMP to further adults. The IDMC will again review the data available 
on this next cohort of adult participants up to  9 weeks following  vect or administration to the 3rd 
participant .  
4.3.2.2.3 Cohort 3  
In the event that there  is no DLE in any participant, the IDMC will recommend administering  vector at the  
highest dose level to a single adult participant.  If th ere is no DLE  after a minimum of 9 weeks, vector  will 
be administered  at the same  dose to 2 further adult participants.  In the event of a DLE in the first adult 
in the cohort, a discussion will be held with the IDMC  to agree a plan of action for administering the 
ATIMP to further adults.  
4.3.2.2.4 Additional considerations  
In the event of a DLE  in one of the 3 participants at a ny given dose,  the cohort will be expanded at the 
same dose level. The IDMC will review the safety data and confirm that additional participants may be 
treated at this dose. T he IDMC may recommend  that the same dose of ATIMP is administered to  
additional participants. T he dose escalation will continue until 3 participants have been either 
administered the highest dose  without any DLEs , or until at least 2 participants among a cohort of 3 to 6 
participants experience DLEs (i.e., ≥33% of participants with a DLE at that dos e level), in which case the 
recommended dose will be th e level  below this toxic dose.  In the event that 1 or 2 DLEs are seen at the 
first dose level, the IDMC may recommend administering a lower dose to that described in the protocol 
to a cohort of participants.  
 
 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 24 of 67 
  
Table 1: Dose escalation table  
Number of 
DLEs  Action  Details  
Low dose     
Participants 1 -3 Participants 4 -6   
0/3  Increase  Give intermediate dose to next cohort of 
participants  
1/3  Remain  Give low dose to another cohort of participants (Pt 
4-6) 
≥ 2/3   Stop  MTD not found. Consider lower dose  
 ≤ 1/6  Increase /stop  Has higher dose been tried?  
No: Give intermediate dose to next cohort of 
participants  
Yes: MTD found – low dose  
 ≥ 2/6  Stop  MTD not found. Consider lower dose  
Intermediate 
dose     
Participants 1 -3 Participants 4 -6 Action  Details  
0/3  Increase  Give high dose to next cohort of participant s 
1/3  Remain  Give intermediate dose to participants 4 -6 
≥ 2/3   Decrease /stop  Give low dose to 3 more participants . If 6 
participants already had low dose, stop. MTD found 
– low dose.  
 ≤ 1/6  Increase /stop  Has higher dose been tried?  
No: Give high dose to participants 1 -3 
Yes: MTD found – intermediate dose  
 ≥ 2/6  Decrease /stop  Give low dose to participants 4 -6. If 6 participants 
already had low dose, stop. MTD found – low dose  
High dose     
Participants 1 -3 Participants 4 -6 Action  Details  
0/3  Remain  MTD found – give high dose to participants in 
confirmation phase  
 1/3  Remain  Give high dose to participants 4 -6 
≥ 2/3   Decrease/stop  Give intermediate dose to participants 4 -6. If 6 
participants already had intermediate dose, stop. 
MTD found – intermediate dose  
  1/6 Stop  MTD found – high dose  
 ≥ 2/6  Decrease/Stop  Give intermediate dose to participants 4 -6. If 6 
participants already had intermediate dose, stop. 
MTD found – intermediate dose  
 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 25 of 67 
  
4.3.2.2.5 Confirmatory safety phase  
MeiraGTx will seek IDMC agreement on the highest dose that can be administered in the expansion 
cohort .  This may include up to 9   participants who may be adults or children . Recruitment into this 
expansion cohort can begin at any dose level up to the IDMC agreed highest dose level .  Children are 
defined as those aged 1 5 and under  in the UK and 17 and under in the US.   Children will be administered 
up to the maximal tolerated dose identified in adults. Having identified a group of children who may be 
willing to participate in the study, the CI will prioritise ATIMP administration to older candidates in the 
first instance. The first child  administered vector will be  monitor ed for s afety  for a period of 9  weeks.  If 
there is no adverse event consistent with the above definition of a DLE  after a minimum of 9 weeks , 
vector  will continue to be a dministered to up to  8 further  participants . In the event of a  DLE as described 
above in the first child, a discussion will be held with the IDMC  to agree a plan of action for 
administering the ATIMP to further children.  
5 Methods  
5.1 Site Selection  
The trial sponsor has overall responsibility for site and investigator selection.  
5.1.1  Study Setting  
The study settings are academic hospitals and academic research centres  selected for thei r ability to 
perform the intervention and assessments required of thi s protocol . Participants will be recruited from 2 
clinical centres: one in the United Kingdom (UK) and one in the United States (US). However, 
participants recruited from the centre in the US will have one clinical assessment performed at a 
separate centre so data will be collected from 3  centres: 1 in the United Kingdom and 2 in the  United 
States of America .  
5.1.2  Site/Investigator Eligibility Criteria  
Once a site has been assessed as being suitable to participat e in the trial, the trial team will provide  
them with a copy of this protocol and the ATIMP Investigator Brochure.  
To participate in the Gene Therapy Trial for LCA OPTIRPE65 , investigators and trial sites must fulfil a set 
of criteria that have been agreed by the Gene Therapy Trial for LCA OPTIRPE65Clinical Management 
Team (CMT ) and that are defined below.  
Eligibility criteria:  
• A named clinician is willing and appropriate to take Principal Investigator responsibility  
• Suitably trained staff are available to recruit participants, enter data and collect samples  
• Suitably trained and certified staff are available to undertake clinical assessments  
• The site has access to all specialised equipment/devices needed for clinical assessments  
• The site should be able to archive traceability data for a minimum  of 30 years post expiry date of 
the ATIMP 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 26 of 67 
  
• The site should have a pharmacy that is able to store, prepare and dispense AT IMP 
appropriately  
• The site shou ld be able to store, prepare,  dispense , and administer  ATIMP appropriately  
Trial sites meeting eligibility  criteria and that are accepted by the CMT as being suitable to recruit to the 
trial,  will be issued with the  Gene Therapy Trial for LCA OPTIRPE65  Trial Mas ter File (TMF)  
documentation to use when applying for local approvals as applicable .  
5.1.2.1  Prin cipal Investigator’s (PI) Qualifications and Agreements  
The investigator(s) must be willing to sign a sponsor’s Clinical Trial Site Agreement and an Investigator 
Agreement to comply with the trial protocol ( confirming their specific roles and responsibilities relating 
to the trial , and that their site is willing and able to comply with the requirements of the trial) . This 
includes confirmation of  appropriate qualifications, familiarity with the appropriate use of any 
investigational products, a greement to comply with the principles of GCP, maintaining up to date GCP 
certification, to permit monitoring and audit as necessary at the site, and to maintain documented 
evidence of all staff at the site who  have been delegated significant trial related  duties.  
5.1.2.2  Resourcing at site  
The investigator(s) should be able to demonstrate a potential for recruiting the required number of 
suitable volunteers within the agreed recruitment period ( i.e. the investigator(s) regularly provide 
clinical care for  the target population) . They should also have an adequate number of qualified staff and 
facilities available for the foreseen duration of the trial to enable them  to conduct the trial properly and 
safely.  
Sites will be expected to complete a delegation of responsibilities log and provide staff contact details.  
5.2 Site approval and activation  
The regulatory authorisations  for the trial requires that the Medicines and Healthcare p roducts 
Regulatory Agency (MHRA) in the UK and US Food and Drug Administration  (FDA) are supplied with the 
names and addresses of all participating site Principal Investigators. Clinical Operations staff at 
MeiraGTx UK II Ltd . will ensure this information is provided to both the MHRA and FDA.  
On receipt of the signed Clinical Trial Agreement and Investigator Agreement, approved  delegation of 
responsibilities log and staff contact details, written confirmation will be sent to the site PI. The trial 
manager or delegate will notify the PI in writing of the plans for site initiation . Sites will not be permitted 
to recruit any participants until a letter for activation has been issued.  
The site must  conduct the trial in compliance with the protocol as agreed by the Sponsor and, by the 
competent authorities, and which was given favourab le opinion by the  UK Research Ethics Committee 
(REC) and local Institutional Review Board ( IRB) in the US . The PI or delegate must document and explain 
any deviation from the approved protocol, and communicate this to the clinical operations  team at 
MeiraG Tx UK II Ltd . 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 27 of 67 
  
5.3 Participants  
5.3.1  Eligibility Criteria  
5.3.1.1  Participant selection  
The eligibility criteria for this trial have been carefully considered and are the standards used to ensure 
that only medically appropriate participants are entered. Participants not meeting the criteria should 
not be entered into the trial for their safety , and to ensure that the trial results can be appropriately 
used to make future treatment decisions for other people with similar diseases or conditions. It is 
therefo re vital that exceptions are not made to these eligibility criteria.  
Participants will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and 
none of the exclusion criteria as defined below.  
The trial CI will confi rm the eligibility of all individual participant s. 
5.3.1.2  Participant Inclusion Criteria  
Inclusion in the trial will be limited to individuals who:  
1. Are aged 3 years or older (although  children , as defined in  Section 4.3.2.2.5 will only be enrolled 
once the MTD has been agreed)  
2. Have early -onset severe retinal dystrophy consistent with RPE65  deficiency  
3. Have homozygous or compound heterozygous missense or null mutations in RPE65  confirmed in 
an accredited laboratory  
4. Have functional or structural evidenc e of photoreceptor preservation  as assessed by  static 
perimetry (for visual field assessment ) and SD -OCT scanning respectively * 
5. Are able to give informed consent or assent, with the guidance of their parent/guardian where 
appropriate : children aged 3 -6 years w ill not be asked to provide assent.  
6. Are able to undertake age -appropriate clinical assessments at the trial sites as specified in the 
protocol  
7. If female and of child bearing potential, are willing to use an effective form of birth control 
(hormonal or barrier method of birth control; or abstinence) for at least 12 months following 
ATIMP administration;  
8. If male, are willing to use barrier and spermicide form of contraceptive or maintain sexual 
abstinence for 12 months following ATIMP administration  
9. Female s of childbearing potential will have a negative pregnancy test on the day of ATIMP 
administration . Participants are considered not of childbearing potential if they are pre -
pubescent, surgically sterile (i.e. they have undergone a hysterectomy or bilatera l 
oophorectomy) or post -menopausal  
10. Are willing to give consent for the use of blood and blood components collected throughout the 
trial for the investigation of immune response s to the ATIMP  
*if the tests having been performed within the 3 months  of enrolm ent and the subject has consented to allow the 
use of those test results, then these tests will not need to be repeated.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 28 of 67 
  
 
5.3.1.3  Participant Exclusion Criteria  
Individuals will be excluded who:  
1. Are females who are pregnant or breastfeeding  
2. Have contraindications for transient immune -suppression by systemic corticosteroids (including 
uncontrolled hypertension, diabetes mellitus, tuberculosis, renal impairment, osteoporosis, 
gastric ulceration, severe affective disorder) or are immunocompromis ed 
3. Have a previous  (within 5 years)  history of gastric or duodenal ulceration, hiatus hernia,  
uncontrolled  gastro -oesophageal reflux or are using non -steroidal anti- inflammatory drugs on a 
regular bas is at the time of screening  
4. Have a known allergy to any of the non -investigational drugs to be used in the trial as defined in 
Section 5.4.1 
5. Have participated in another research study involving an investigational medicinal therapy  for 
ocular disease  within the last 6 months  
6. Have any other condition  that the PI  considers makes them inappropriate for entry into the trial  
7. Have had intraocular surgery within 6 months of screening  
8. Have an ocular or systemic disorder that may preclude subretinal surgery and/or interfere with 
interpretation of the study results  
9. Are unwilling to consider the possibility of entry into a subsequent longer term follow up study  
5.3.1.4  Eligibility Criteria for Individuals Performing the I nterventions  
Individuals performing the interventions will be limited to those qualified by training and experience to 
perform those interventions.  
Surgery will only be performed by a qualified vitreo -retinal surgeon. The ATIMP will be administered by 
designated individual s at each study site  to promote consistency of the intervention . The CI has 
developed  a training programme that involves any designated individuals being trained in person  by the 
CI. This may involve observations of the procedure being performed in the UK or the US . The completion 
of this training is one of the criteria that will be satisfied  prior to site activation.  
5.3.1.5  Co-enrolment Guidance  
Individuals who have participated in another research study involving an investigational medicinal 
therapy  for ocular disease  within the last 6 months , will not be eligible for enrolment in this s tudy.  
5.3.1.6  Screening Procedures  
Written informed consent to enter into the trial must be obtained from participants, or 
parents/guardians/person with legal responsibility (including legal authorities) for children , after 
explanation of the aims, method s, possible benefits and potential hazards of the trial and BEFORE  any 
trial- specific procedures are performed or any blood is taken for the trial. The only procedures that may 
be performed in advance of written informed consent being obtained are those th at would be 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 29 of 67 
  
performed on all individuals in the same situation as a usual standard of care. Data obtained previously  
from subjects enrolled on the MGT005 LCA Natural history study may be used for screening and / or 
baseline assessments if testing was perfor med within the screening/bas eline window of this trial and 
the subjects have provided informed consent for the use of the prior obtained results.   
5.3.1.6.1  Informed Consent Procedure  
Written informed consent will be taken from each participant (or parent/guardian if the participant  is a 
child) by the chief/principal investigator or delegated clinician following appropriate explanation of the 
aims, methods, possible benefits and risks of the study. The Investigator or designee will explain that the 
participants are under no obligation to enter the trial and that they can withdraw at any time during the 
trial, without having to give a reason, and without their clinical care being affected. No clinical trial 
procedure will be conducted prior to taki ng consent from the participant.  
The consent process will be managed during at least 2 meetings. At an initial meeting, information will 
be presented to potential participants in a form appropriate to their level of understanding. In the case 
of children,  they and their legal guardian(s) will be offered the support of a family support counsellor  (in 
the UK) or genetic counsellor (in the US) . Potential participants will be provided with the relevant 
participant  information sheets (or audio versions) and giv en time (a minimum of 24 hours) to consider 
their decision.  
At a subsequent meeting , potential participants will be provided with a further opportunity to ask 
question s and to sign the consent form. Children will be invited to give their verbal ( and noted in their 
medical notes) or written assent to participation  where this is age appropriate (i. e. children aged over 6 
years) . Where children aged over 6 years do not assent , they will not be entered into the trial. A copy of 
the signed Informed Consent form will be provided to the participant. The original signed form will be 
retained at the study site and a copy placed in the medical notes.  
If new safety information results in significant changes in the risk/benefit assessment, the participant 
information sh eet and consent form will be reviewed and updated if necessary, and participants will be 
re-consented as appropriate.  
Children who become of adult age ( i.e. 16 in the EU, 18 in the US) during the study will be reconsented 
as adults at the time of the ir next visit.  
5.3.1.6.2  Screening Period  
Screening procedures will take place only after the informed consent form has been signed by the 
participant /parent/guardian.   However, if test results are available from the subject’s  participation in 
the MGT005 LCA nat ural history study, and the subject has consented to allow the use of those test 
results, then those screening tests will not need to be repeated.  
Participants will undergo genetic screening for RPE65  mutations at an accredited laboratory prior to 
enrolment.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 30 of 67 
  
Participants will be screened to ensure there are no contra- indications for transient im mune 
suppression, in particular:  hypertension, diabetes mellitus, tuberculosis, renal impairment, 
immunocompr omise d status , osteoporosis, gastric ulceration or severe affective disorder.  
Screening assessments are listed below (and set out under the column headed ‘S creening’ in the Trial 
Assessments  Table 2 , Section 5.6):  
1. Genetic testing  
2. Medical history and conc omitant medication  
3. Physical examination  
4. Vital s igns (including height and weight)  
5. Ocular examination  
6. Visual acuity  
7. Contrast Sensitivity  
8. Spectral Domain Optical Coherence Tomography (SD -OCT) imaging  depending on age, as a 
greater degree of  co-operation is needed compared to SD -OCT)  
9. Electrophysiological assessment  
A letter from the general practitioner detailing the health status of the  participant may be requested if 
the clinician deems it appropriate to confirm eligibility for the trial.  
These assessments must have been completed within 3 months prior to enrolment. In addition, females 
of child bearing potential will undergo a pregnancy test at screening and again on the day of  ATIMP 
administration . 
5.3.1.6.3  Enrolment  
Participants who fulfil the inclusion criteria based on the results of all screening assessments and 
pregnancy test will be enrolled in the trial. The ATIMP will be administered within 3 months of 
enrolment. If the ATIMP is not delivered within 3 months of  enrolment, all screening tests with the 
exception of genetic testing and electrophysiological assessment will be repeated and eligibility for 
enrolment re- assessed.  
Participants who withdraw or are withdrawn from the study for any reason prior to ATIMP 
administration may be substituted in the study.  
5.4 Interventions  
5.4.1  Products  
5.4.1.1  Name and Description of Investigational Medicinal Product(s)  
AAV2/5 -OPTIRPE65  is an advanced therapy investigational medicinal product; specifically , a gene 
therapy pro duct.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 31 of 67 
  
It consists of a linear single strand of DNA packaged in a recombin ant adenovirus -associated virus  (rAAV) 
protein capsid of serotype 5. The rAAV.hRPE65p.hRPE65 incorporates the wild -type AAV inverted 
terminal repeats that provide the packaging signal , a cDNA encoding human RPE65 , the human RPE65  
promoter, a SV40 intron sequence, and a SV40 polyadenylation signal. The icosahedral capsid consists of 
three related AAV5 capsid proteins, VP1, VP2, and VP3. AAV has a compact macromolecular structure 
and for ms stable viral particles approximately 20 nm in diameter. The vector particles are replication -
incompetent.  
RPE65  is an isomerase expressed in the retinal pigment epithelium (RPE) that cataly ses the isomerization 
of all- trans -retinyl esters to 11 -cis-vitamin A, and is a critical component of the visual biochemical cycle 
that regenerates visual pigment after light exposure. The lack of functional RPE65  leads to a deficiency in 
11-cis-retinal, the light -sensitive chromophore that binds to opsin, and results  in diminished rod 
photoreceptor function. Recombinant AAV -mediated gene transfer of a normal RPE65  gene to the RPE 
leads to stable, long- term transgene expression and improves visual function in rodent and dog models 
of disease. The study agent is based o n the virus vector that led to improved night vision in a previous 
clinical trial (Bainbridge et al . 2008, Bainbridge et al . 2015); the original configuration has been modified 
to improve efficiency of RPE65  gene expression at least 300 -fold.  
5.4.1.2  ATIMPs Classified as Genetically Modified Organisms  
The ATIMP ( AAV2/5 -OPTIRPE65 ) is classified as a genetically modified organism under the Genetically 
Modified Organisms (Contained  Use) Regulations 2000 . 
The Health and Safety Executive (HSE)  must be notified of e ach UK clinical trial site administering the 
ATIMP for first use of premises for genetic modification activities before the activities commence. A risk 
assessment of the activities has been carried out and has been reviewed by the local Genetic 
Modification Safety Committee (GMSC). Internal approval at site for the GMO activities has been gained.  
Each clinical trial site administering the ATIMP in the US must obtain local Institutional Biosafety 
Committee approval to administer recombinant nucleic acid molecule material to human subjects. Trial 
sites that receive support for recombinant or synthetic nucleic acid molecule research from the National 
Institutes of Health (NIH) mu st submit the protocol to the NIH Office of Biotechnology Activities (OBA) 
for review prior to initiating trial activities.  
5.4.1.3  Source of ATIMPs  
The ATIMP has been manufactured at the Wolfson Gene Therapy Unit (WGTU)  facility of the UCL Gene 
Therapy Consortium at the UCL Cancer Institute in accordance with current Good Manufacturing 
Practice for clinical trial materials . The manufacturer will perform analytical testing and provide QP 
certification  for release .  
5.4.1.4  Preparation and Labelling of the Investigational Medicinal 
Product 
Preparation and labelling of the investigational medicinal product will be completed in accordance with 
the relevant GMP guidelines  and MeiraGTx UK II Ltd . procedures .  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 32 of 67 
  
The ATIMP is  a recombinant serotype 2/5 adeno -associated viral vector containing a human RPE65  cDNA 
driven by a fragment of the human RPE65  promoter. The manufacturer (WGTU) will perform analytical 
testing and provide QP certification  for release . Aliquoting into vials and labelling of the ATIMP is the 
responsibility of WGTU. The WGTU is also responsible for testing, QP release and storage of the final 
ATIMP. Performance of certain release assays is contracted to approved contractors of the WGTU.  
US Federal regulation s require that a drug should be the subject of an approved marketing application 
before it is transported or distributed across state lines. As such, in order to ship INDs to investigators, 
the sponsor will submit an IND application in order to obtain an e xemption from the FDA with regard to 
the marketing approval requirement.  
5.4.1. 5 Description and Justification of Route of Administration  and Dose  
Efficient transduction of the target retinal pigment epithelial cells requires the ATIMP ( AAV2/5 -
OPTIRPE65 ) to be administered to the subretinal space. Delivery of vector suspension to the subretinal 
space will be performed following a standard surgical vitrectomy. This will involve a 3 -port pars plana 
vitrectomy followed by injection of vector suspension usin g a fine cannula through 1  or more small 
retinotomies into the subretinal space, resulting in temporary retinal detachment. Previous gene 
therapy clinical trials have shown that the bleb of subretinal vector suspension can be expected to 
resolve spontaneou sly over the course of the first 24 to 48 hours postoperatively as the fluid is absorbed 
by the underlying retinal pigment epithelium. Risks to visual function will be minimized by controlling 
the area of vector delivery, and by leaving the contralateral f ellow eye untreated. Vitrectomy surgery is 
a standard technique, commonly performed for a wide range of indications. Injection of fluids under the 
retina is less commonly performed but is a standard step for delivery of surgical dyes and therapeutic 
thromb olytic agents to the subretinal space.  
Comparative experiments in Rpe65 -deficient mice have shown that AAV2/5 -OPTIRPE65 is 300 -fold more 
potent than the AAV2/2 -hRPE65 vector used previously.   Given that AAV2/5 -OPTIRPE65 is at least 300 
fold more potent in mouse rescue experiment than AAV2/2 -hRPE65, administration of 1  x 1011 vg/eye of 
AAV2/5 -OPTIRPE65 would thus result in an approximately 30 -fold increase in effective  RPE65 delivery 
compared with that resulting from administration of 1  x 1012 vg/eye of AAV2 /2-hRPE65 
(rAAV2/2.hRPE65p.hRPE65) in the first clinical study (10 -fold lower dose of a vector that is 300 -fold more 
potent).   In addition, as a 7 -fold more efficient translation is seen with the optimized vector in human 
cells, it is possible that greater  improvements in ERG and retinal survival may be observed at the proposed 
starting dose.   Importantly, based on existing knowledge, it is not anticipated that this enhanced 
translation efficiency and potency of the vector would be detrimental to the patien ts.  This approach is 
intended to maximize potential benefit for patients participating in the study by commencing dosing at a 
level that is theoretically effective.  
The intended administration volume of 1mL is considered appropriate to enable optimal expo sure of 
target RPE cells to the vector, even in young children. The location of retinotomies will be determined 
with the aim of exposing those RPE cells that support overlying viable photoreceptor cells as determined 
by optical imaging. Whilst the surgical technique is designed to optimise the possibility of benefit, any 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 33 of 67 
  
concern arising intra- operatively about possible adverse events will be appropriately addressed in the 
interests of safety, and any deviations from protocol recorded.  
5.4.1.6  Name and Descr iption of Each Non -Investigational Medicinal Drug 
(NIMP)  
1. Cefuroxime or cefazolin  or vancomycin antibiotic  given at usual dose at end of surgery (standard dose  
as prophylaxis for post -operative infection)  
2. Betamethasone or dexamethasone given at usual dose at end of surgery (standard dose  as 
prophylaxis for post -operative inflammation)  
3. Chloramphenicol 0.5% or ofloxacin (topical antibiotic) 4 times daily for 7 days following ATIMP 
administration  
4. Dexamethasone 0.1% (topical steroid) 4 times daily for 4 weeks , then 2 times daily for a further 2 
weeks (weeks 4 to 6)  following ATIMP administration  
3 and 4 above will be administered to minimise inflammation and protect against infection 
postoperatively.  
5. Omeprazole:  
• In adults 20mg per day f or 8 weeks  
• In children weighing 5  kg to less than 10 kg (11 lb to less than 22 lb): 5 mg taken once per day  
• In children weighing 10 kg to less than 20 kg (22 lb to less than 44 lb): 10 mg taken once per day  
In children weighing 20 kg (44 lb) or more: 20 mg taken once per day  
6. Prednisolone  or Prednisone  (oral steroid) as prophylaxis against potential intraocular immune 
responses:  
For adults 30 mg daily for one week prior  to ATIMP administration  
Following the ATIMP administration as follows:  
• 60 mg daily in week 1  
• 40 mg daily in week 2  
• 30 mg daily in week 3  
• 20 mg daily in week 4  
• 15 mg daily in week 5  
• 10 mg daily in week 6  
• 5 mg daily in week 7  
• 2.5 mg daily in week 8  
 
Children will be prescribed a tapering regimen of predniso lone tailored according to age an d weight, and 
in addition intravenous methylprednisolone  30mg/kg  on the day of surgery (maximum total no more 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 34 of 67 
  
than 1g). A further dose of  methylprednisolone  may  be administered at week 4 in the presence of signs 
of intraocular inflammation. The detailed tr eatment regimen is described in a clinical management plan.  
All N on Investigational Medicinal Product s (NIMPs)  are licensed within the EU  and US  and will be 
procured from standard hospital stock . 
Sites will maintain a system that allows adequate reconstruc tion of NIMP movements and permits 
recording of which participants received which NIMPs during the trial, with an evaluation of the 
compliance where necessary.  
5.4.2 Protocol defined clinical s chedule  
5.4.2.1 Baseline Assessments  
Assessment of visual funct ion and retinal imaging of both eyes will be performed preoperatively as 
outlined in Section 5.6 (Table 2 , Trial A ssessments ). For assessments requiring multiple baselines, testing 
is preferred  on separate days  within a maximum 3 -month period to allow for day to day variation and 
test retest variability for individual participants.  However, it is acknowledged that a balance will be 
achieved between what is pragmatic and appropriate for the different tests on an individual basis. Each 
set of baseline measurements may take up to 3 days to perform in total.   In some instances, results for 
protocol specified baseline tests may be available through a subject’s prior participation on the MGT005 
LCA natural history stud y.  As such, if the subject provides informed consent to use the results from the 
previously conducted tests, then these assessments will not need to be repeated at baseline.   
Visual assessments results  will be sent for reading and analysis to independent  reading centres within 
the UK and US.  For both sites  Imaging for  OCT and Fundus photography  will be reviewed by the site 
team s but also sent for independent analysis by the Reading Centre , Queens University, Belfast during 
the course of the trial . Adapti ve optics images will be sent to the Medical College of Wisconsin for 
reading and Octopus perimetry and Microperimetry will be sent to the Oregon Health and Science 
University Casey Eye Institute reading centre. All images will be saved under pseudo anonymised patient 
identifiers and images will only be taken of the patient’s eye to ensure that patients  will remain 
unidentified.  
Up to 1 0 mL of blood will be sampled in order to assess baseline levels of T -cell res ponses to AAV5 and 
of circulating antibodies against AAV serotype 5 and RPE65  so that immunological responses to vector 
capsids and transgene product might be determined following vector administration (collectively 
described as serology in Table 2, Trial A assessments). We anticipate that the majority of participants 
will have no detectable pre -existing circulating antibodies against AAV5 or RPE65 . The presence or 
absence of circulating antibodies will not affect recruitment of the participant . All serolog y tests will be 
carried out at the sponsor’s approved  Laboratory  in the UK . 
There is wide variability in the ability of children of different ages to undertake some  of the proposed 
tests; the evaluations for children will be restricted to those tests that they are able to perform reliably.  
Tests that will be performed in all participants are:  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 35 of 67 
  
1. Serological tests  
2. Blood pressure  
3. Haematology  
4. Biochemistry  
5. Ocular examination  
6. Intraocular pressure  
7. Colour fundus photography  
8. Spectral Domain Optical coherence tomography ( SD-OCT) 
9. Fundus Autofluorescence imaging (FAF)  
10. Best corrected visual acuity  
11. Full-field electroretinography (ERG)  
12. Pattern electroretinography (PERG)  
 
Tests that will be performed where possible are:  
13. Contrast sensitivity  
14. Reading assessment  
15. Colour vision testing  
16. Microperimetry (mesopic  and scotopic ) 
17. Octopus900 full -field static perimetry  
18. Vision -guided mobility  
19. Multifocal electroretinography (mfERG)  
20. Adaptive optics (AO) imaging  
21. QOL questionnaire s 
Further details of clinical assessments can be found in the OPTIRPE65  study manual .  
(i) Ocular examination and retinal imaging  
Ocular examination by  slit lamp biomicroscopy will be used to assess the anatomical integrity of the 
eyes and quantif y any intraocular inflammation. During the examination, intraocular pressure will be 
determined by tonometry.  
Retinal imaging includes colour fundus photography  (ETDRS 7 standard fields) , FAF, SD-OCT, and AO 
imaging. FAF imaging allows visualisation of the retinal pigment epithelium (RPE) by taking advantage o f 
its intrinsic fluorescence derived from its lipofuscin content. SD -OCT imaging enables measurement of 
retinal thickness and provides information about the integrity of the layers of the retina. AO imaging 
provides direct visualization of the photorecepto r and RPE mosaics in vivo . 
(ii) Functional and Participant -Related Outcome assessment s 
Where possible the participant will complete an age -appropriate Impact of Visual Impairment (IVI) vision -
specific quality of life questionnaire , and EQ5D -5L and EQ -5D-Y questionnaire s. 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 36 of 67 
  
Reading ability , including reading acuity, maximum reading rate, and critical print size will be assessed 
with MNRead and International Reading Speed Texts.  
Best -corrected ETDRS visual acuity will be measured in each eye. Contrast sensitivity will be measured 
using the Pelli -Robson chart.  
Colour vision testing will be undertaken using plate tests and computerised tests probing colour 
discrimination.  
Retinal sensitivity will be determined using Octopus  900 full- field static perimetry  and/or full field 
stimulus testing (FST)  where available,  and microperimetry  (mesopic and scotopic ). Where available, FST 
may be performed for enrolled paediatric patients at participating sites . The retinal locus of fixation will 
also be accurately determined us ing microperimetry.  
Vision -guided mobility will be assessed by measuring the ability of each participant to navigate a simple 
route in a range of controlled illuminances.  
Full-field electroretinography (ERG), pattern ERG (PERG) and multifocal ERG (mfERG) w ill be performed 
according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standards to assess 
both generalised retinal (RPE, rod and cone systems) and isolated macular function. Modified ISCEV 
protocols may be necessary in yo ung children using internationally recognised modified protocols.  For 
young children, this procedure may be performed under general anaesthesia. ERG data will be analysed 
and interpreted by dedicated full -time Clinical Visual Electrophysiology  Consultants with extensive 
experience and who are directly involved in determining ISCEV standards . 
5.4.2.2 ATIMP administration  Procedures  
The ATIMP administration  procedures described in the protocol are what is broadly intended to occur 
during surgery. Anticipated procedures may be modified on a case -by-case basis in the interests of 
safety, and these modifications will be documented in the operation notes and CRF. Consent to record 
the surgery will be requested of the participant . Intraocular surgery will be recorded using a video 
camera via the operating microscope. Relevant recordings and images  will be stored alongside the trial 
database.  
5.4.2.2.1 Preoperative procedure  
For prophylaxis against potential intraocular immune responses to the AT IMP, part icipants will be 
prescribed a course of daily oral prednisolone (or other as appropriate) commencing at a dose of 30mg  
daily for 1 week prior to AT IMP administration.  
Preoperative procedures and i ntraocular administration of ATIMP  will be as described in the 
OPTIRPE65  study manual  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 37 of 67 
  
5.4.2.2.2 Operative procedure  
The choice of eye that the vector is delivered to will be made between the participant and PI. It is 
anticipated that this will be th e poorer -seeing eye but this will be dec ided upon in discussion with the 
participant.  
The recom binant vector will be delivered in the form of a suspension of viral vector particles injected 
intraocularly (subretinally) under direct observation using an operating microscope. This procedure will 
involve 3 -port pars plana vitrectomy followed by injection of vector suspension using a fine cannula 
through 1 or more small retinotomies into the subretinal space. The procedure may be performed under 
general or local anaesthesia at the discretion of the operating surgeon and the participant.  
The eye and face will be prepared using povidone iodine solution. The face and eye will be covered with 
an adhesive sterile plastic drape. An opening will be made at the point of the palp ebral fissure and a 
wire specu lum inserted to retract the upper and lower eyelids. The speculum and all intraocular 
instruments will be sterilised according to standard local operating procedures. An intraocular infusion 
cannula will be placed to maintain a normal globe volume by infus ion of fluid. 2 further pars plana 
sclerotomies will be placed to accommodate an endo -illumination probe and vitreous cutter. The fundus 
will be viewed by means of a BIOM indirect viewing system or a contact lens. The posterior hyaloid will 
be peeled anter iorly and the vitrectomy completed using the vitreous cutter.  
The specific area of retina to be targeted in each  participant  will be pre -determined according to the 
degree and distribution of retinal degeneration defined by pre -operative assessments. Intr aocular 
administration o f the viral vector suspension ( AAV2/5 -OPTIRPE65 ) will be performed using a cannula 
attached to a syringe. The cannula will be advanced through the retina at sites pre -determined in each 
participant according to the area of retina to  be targeted. Where possible, the vector will be targeted to 
exclude the fovea. If appropriate, the bleb of vector may be manipulated to the target area using a fluid -
air exchange. Under direct visualisation the vector suspension (1.0 x1011 to 1. 4 x1012 vg/mL; up to a 
maximum volume of 1 m L) will be injected under the neurosensory retina causing a localised retinal 
detachment. The first 3 adult participants will receive the low dose (1.0 x1011 vg/mL), with 3 subsequent 
adults receiving the intermediate dose  (3.0 x1011 vg/mL) and 3 subsequent adults receiving the high 
dose (1.0 x1012 vg/mL) according to the dose -escalation criteria. Children will be included only after 
safety has been appropriately determined in adults. The injection of vector suspension may be preceded 
by injection of a small volume of saline  solution (0.1 to 0.5 m L) to establish a “bleb” facilitating targeted 
delivery of vector suspension to the subretinal space and minimising possible exposure of the choroid 
and vitreous cavity to vector. T he injection retinotomy is designed to be self -sealing with minimal reflux. 
Following administration of vector suspension, the area of the induced retinal detachment will be 
documented by fundus photography.  
On the basis of the findings of previous clinical studies, it is predicted that retinal blebs (localised retinal 
detachments) generated  by subretinal vector delivery will resolve spontaneously with retinal re -
attachment during the first 48 hours, without the need for retinopexy or intrao cular tamponade. 
However, any unplanned peripheral retinal breaks will be managed appropriately using cryo - or laser-
retinopexy and injection of an appropriate tamponade agent at the time of surgery, or as part of a 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 38 of 67 
  
subsequent procedure. Sclerotomies may b e closed using sutures at the surgeon’s discretion. Standard 
doses of cefuroxime antibiotic and betamethasone  or their equivalent  will be administered 
subconjunctivally as prophylaxis against postoperative infection and inflammation respectively. The 
opera ted eye will be dressed with a pad and shield.  
5.4.2.3 Subsequent Assessments  
Surgery may be performed, as is conventional for intra -ocular procedures, on a day -case basis. 
Participants will subsequently be managed as outpatients, though hospital -based acc ommodation may 
be used for convenience.  
On the first postoperative day a clinical ocular examination will be performed. In particular, visual acuity, 
intraocular pressure, any postoperative intraocular inflammation and the area of any residual retinal 
bleb  will be documented. Fundus photography and SD -OCT scanning will be performed  on the day 1 and 
subsequent assessments .  
A standard post -vitrectomy treatment regimen of topical antibiotic ( e.g., chloramphenicol 0.5% qds for 7 
days), and corticosteroid ( e.g. dexamethasone 0.1% qds for 4 weeks  and then bd for a further 2 weeks ) 
will be commenced to minimise inflammation and protect against infection postoperatively. Intraocular 
pressure of greater than 30 mmHg will be managed using appropriate ocular antihypertensive therapy.  
Participants will be maintained on oral prednisolone  (or other as appropriate)  for 8 weeks following 
administration of vector suspension as described above ( Section 5 .4.2.2 , Preoperative procedure ). The 
possible development of steroid -induced adverse effects will be monitored regularly. In particular, blood 
pressure, blood glucose, renal function and liver function will be measured.  
Female participants of childbearing potential and male participan ts with partners of childbearing 
potential will be advised to use a double barrier method of contraception for 12 months after surgery.  
Both safety and efficacy of the ATIMP will be evaluated  at various time points up to 6  months after 
ATIMP delivery. Evaluation will occur primarily by ocular assessments. The nature and schedule ( Section 
5.6, Study assessments ) of these is described below.  
Participants will subsequently be invited to enrol  in a 5 -year follow -up study to determine longer term 
safety and efficacy.  
(i) Clinical assessment of intraocular inflammation  
The degree of intraocular inflammation will be assessed by slit -lamp biomicroscopy at each time point. A 
temporary intraocular inflammatory response is predictable following vitrectomy surgery. This is 
typically evident clinically on slit lamp biomicroscopy as ‘flare’ and cells in the anterior chamber and can 
be of moderate (2+) intensity. The degree of intraocular inflammation is expected to decline during the 
course of the first 8 weeks following the surgical procedure at which time the routine topical and 
systemic immunosuppression will be discontinued. Prolonged or recurrent intraocular inflammation will 
be managed conventionally by further topical and/or systemic immunosuppression.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 39 of 67 
  
(ii) Evalu ation of immune responses  
Up to 10 mL of blood will be sampled to measure immune response. Blood serum will be isolated and 
analysed. Residual samples will be stored in a n approved  laboratory  designated by the sponsor for use in 
future ethically approved re search, with the participant’s consent.  Immunological assays  will be 
performed as outlined in Section 5.6  (Trial A ssessments) to investigate antibody responses to AAV 
capsid proteins and to RPE65  protein . Investigators performing these analyses will be masked to 
participant ’s identity.  
(iii) Evaluation of biodistribution  
Systemic biodistribution of vector genomes will be assessed at as outlined in Section 5.6  (Trial 
Assessments ) by PCR analysis of tears from the study eye (a compressed cellulose sponge placed under 
the eye lid until swollen), saliva (a minimum of 100 μL) and serum  (100 μL). Th is test will be carried out 
in the institutional laboratory  in the UK . 
(iv) Assessment of visual function and retinal  imaging  
Assessment of visual function and retinal imaging will be performed as outlined in Section 5.6 (Trial 
Assessments ) at baseline and at intervals following intervention. These assessments will be scheduled 
over a period of a day f or visits at day 1,  day 3, week 1 , week 2, week 4 and week 6 after surgery, and up 
to 4 days for baseline examinations, and 3 months  and 6 months following intervention.  For day 1 and 3 
refraction cannot reliably be measured. Therefore,  the most recent refraction measuremen t will be 
used.  
All participants (adults and children) will need to be able to perform visual acuity testing and SD -OCT 
imaging reliably. Other clinical assessments will be undertaken as appropriate for each participant ’s 
ability; since there is wide variability in the ability of children of different ages to undertake these tests, 
the evaluations for children may be restricted to those tests that they are able to perform reliably.  
Additional investigations may be performed for appropriate clinical manageme nt of any adverse events.  
5.4.2. 4 Laboratory Procedures  
Blood serum will be  processed within the UCL Institute of Ophthalmology to assess an y immune 
responses to the ATIMP. Serum will be analysed for:  
1. anti-AAV5 antibodies by ELISA  
2. anti-human RPE65  antibod ies by ELISA  
3. anti-AAV5 neutralising antibodies  
Blood serum , saliva and lac rimal fluid will be processed at the  UCL Institute of Ophthalmology t o assess 
dissemination of vector after delivery, where the number of rAAV  vector genome copies will be 
measured by polymerase chain reaction (PCR).  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 40 of 67 
  
Whole blood will be processed at the National Genetics Reference Laboratory  in the UK, or a CLIA -
accredited molecular diagnostic laboratory in the US,  for RPE65  mutation screening.  Standard 
haematology and biochemistry screen will be carried out at the Trust associated laboratories , or an 
accredited laboratory in the United States .  
5.4.3 Dispensing  
5.4.3.1  Receipt and Storage of the Investigational Medicinal Product  
The product, which is stable at ≤– 50° Celsius, will be stored at < -70° Celsius in secure temperature 
controlled and monitored -800 Celsius freezers  at the sponsor’s delegated storage facility . Shipping of 
ATIMP to study sites will be on dry ice, accompanied by a tempe rature -monitoring device.  
On the day of administration of the ATIMP, the prescribed number of vials will be transferred to the 
operating theatre according to study specific working instructions . The ATIMP will not be refrozen upon 
thawing prior to the surgical procedure  and any remaining product will be discarded according to local 
procedures.  
5.4.4  Dos ages  
5.4.4.1  Dosages and dosage modifications 
Trial participants will receive 1  of 3 different doses of ATIMP within the range proven to be safe in the 
preclinical animal stud ies.  
1) low dose   1mL at 1.0 x1011 vg/mL  
2) intermediate dose  1mL at 3.0 x1011 vg/mL  
3) high dose   1mL at 1.0 x1012 vg/mL  
The ATIMP has been produced and stored at the concentration of  1.4 x 1012 vg/mL . Vector will be  
diluted immediately prior to intraocular administration  in Hartmann’s solution at the time of 
administration for all 3 doses.  For participants receiving the low dose of 1.0 x1011 vg/mL, the ATIMP will 
be diluted 1 4-fold in Hartmann's solution. For participants receiving the intermediate dose of 3.0 x1011 
vg/mL, the ATIMP will be diluted 4.6 -fold in Hartmann's solution. For participants receiving the high 
dose of 1.0 x1012 vg/mL, the ATIMP will be administered diluted  1.4-fold. In each case, up to 1.0 mL 
ATIMP at the appropriat e titre will be administered to the target area.  The CI/PI will prepare the 
appropriate dilution and this will be checked in the operating theatre by a second clinician prior to 
administration. The check will be recorded in the participant’s source data no tes. 
Further details for dose -escalation criteria are included in S ection 4.3.2. 
5.4.5 Accountability  
The ATIMP will be prescribed for a particular participant by 1 of the Investigators  and handled according 
to the ATIMP Management Plan applicable for each  site.  
For accurate accountability,  the following information will be recorded when the ATIMP is administered:  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 41 of 67 
  
i. Date 
ii. Participant  identification  number  
iii. Batch number  
iv. Volume and dose of vector administered  
v. Name of Principal Investigator or delegated surgeon  administering ATIMP  
vi. ATIMP name/code  
vii. Trial reference code  
viii. Expiry date  
Surplus ATIMP will be destroyed according to existing SOPs, using methods suitable for destruction of 
genetically modified organisms.  
A system will be  set-up to ensure the traceability of the ATIMP from the starting material, through to 
administration to the subject and destruction or final disposition. A comprehensive ATIMP management 
plan and associated SOPs and forms will be in place to ensure that t he required accountability and 
traceability data is collected and retained.  
5.4.6 Compliance and Adherence  
Full compliance is expected since the ATIMP will be surgically delivered by the CI or a delegated vitreo -
retinal surgeon.  The aim is to target the administered volume into the subretinal space. Any deviation 
from this will be noted in the CRF. See section 5 .4.8 (Overdose of trial medication) about the assessment 
of adherence to the protocol defined delivery of the product.  
5.4.7 Concomitant Care  
Concomitant use of other medications should be avoided unless clinically necessary and  should be used 
with caution , and appropriately documented on study logs where used. All concomitant medications 
(including steroids) must be record ed in the eCRF f rom the day of informed consent.  
5.4.8 Overdose of Trial Medication  
An intraocular administration of ATIMP will be performed by the operating surgeon (CI  or a delegated 
vitreo -retinal surgeon ). The volume of vector delivered to the target site will be measured by the syringe 
plunger and recorded in the CRF.  
Any overdose will be repo rted to the sponsor. This is a P hase I/II exploratory study and the possible 
impact of any overdose will be considered in the final analysis. Given that this is  a single administration 
study, the trial subject will not be withdrawn but the collected data will be analysed separately in 
comparison with the data from the participant ’s baseline assessments and from other treated 
participants. Any concern about accura te dosing may warrant suspension of the trial pending 
appropriate investigation.  
Overdose of ATIMP may result in development of Adverse Events of various severities that will be 
recorded and reported as outlined in Section  5.11.3.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 42 of 67 
  
5.4.9 Protocol Discontinuation  
5.4.9.1 Subject Withdrawal  
In consenting to the trial, participants ar e consenting to ATIMP administration , trial follow -up and data 
collection.  
As participation in the trial is entirely voluntary, the  participant  may choose to discontinue  trial 
participation at any time without penalty or loss of benefits to which they would otherwise be entitled. 
Although not obliged to give a reason for discontinuing their participation , a reasonable effort should be 
made to establish this, whilst remain ing fully respectful of the participant’s rights.  
Should a participant withdraw from the study, a withdrawal CRF documenting the reason for withdrawal 
will be completed, in addition to the procedures and CRF for the final visit ( 6 month) assessments, with 
the participant’s consent. However, participants will be encouraged to participate in any of the planned 
schedule for the trial whilst arranging a visit for routine (annual) clinical follow -up. 
Participants who withdraw prior to vector administration will be regarded as off- protocol and their 
primary ophthalmologist will resume normal standard of care. Any subject who withdraws prior to 
administration of ATIMP may be replaced in the study. Participants who withdraw from the study after 
vector administration  will be encouraged to have follow -up investigations with their consent, so that the 
consequences of vector administration can be documented and the data analysed. The CMT may choose 
to replace a subject who withdraws after vector administration.  
5.4.9.2 Trial Stopping Rules  
The Chief Investigator and Sponsor retain the right to terminate the study. Specific circumstances that 
may precipitate such termination are as follows:   
1. Unanticipated adverse medical experience in this or other studies indicating a potential health 
hazard caused by the ATIMP  
2. Significant protocol deviation and lack of compliance and cooperation on the part of an 
investigator, which endangers the safety of the participants or the validity of the trial 
3. Death of a participant at any time point after ATIMP administration that is possibly, probably, or 
definitely related to the ATIMP  
4. The occurrence of a non -ocular malignancy at any point after gene transfer that is possibly, 
probably, or definitely related to the ATIMP  
5.5 Outcome s 
5.5.1  Primary Outcomes  
The primary outcome is defined as any of the below occurring during the 9  weeks following 
administration, at least possibly related to the ATIMP, not surgery alone:  
• Reduction in visual acuity by 15  ETDRS  letters  or more  
• Severe unresponsive inflammation  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 43 of 67 
  
• Infective endophthalmitis)  
• Ocular malignancy  
• Grade III or above non -ocular SUSAR. (See Section 5.11.3 ) 
5.5.2  Secondary Outcomes  
The secondary outcomes are measures of the efficacy of the ATIMP; these will be performed on an 
indiv idual participant basis and will be descriptive in nature. Secondary outcomes are:  
• Any improvements in visual function from baseline that are  greater tha n the test -retest 
variation and are sustained for at le ast two consecutive assessments . 
• Any improvement in retinal function from pre -intervention  that is  greater than the test- retest 
variation and measurable by electroretinography (ERG) . 
If no ERG  is previously detectable, then the presence of any reproducible response with appropriate 
wavefo rm would be significant. If an ERG is there to start with, any of the following would be significant: 
an improvement in amplitude of >50 % in DA 0.01 b -wave (rod system sensitivity); bright flash DA 10 a-  
wave (photoreceptor improvement); the 30Hz flicker;  and the LA 3.0 photopic a - and b -waves. In terms 
of timing: > 3ms improvement in photopic parameters and bright flash DA 10 a -wave; 3 -6ms for the DA 
0.01 and DA 10.0 b -waves.  
• Quality of life will be measured by the Impact of Visual Impairmen t (IVI) questionnaire and the 
EQ5D - 5Land EQ -5D-Y
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 44 of 67 
  
5.6 Trial Assessments  
Table 2: Trial assessments  
 Screening  Baseline  ATIMP 
admin  D1   D3  W1  W2  W4  W6  W9 W12  W24  
Flexibility of schedule ( + days)  - 3 
months  Day 0  + 
0D + 
1D + 
2D + 
4D + 
7D + 
7D + 
7D + 
14D +  
14D 
Visit number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Informed consent  •              
Physical exam  •              
Medical history  •       • • • • • • • 
Eligibility determination  •              
IMP administration      ★          
Adverse event review   • • • • • • • • • • • • • 
Concomitant medication review  • • • • • • • • • • • • • • 
Genetic screening  •              
Pregnancy test  •    •          
Vital signs (including height and 
weight)5 • •    •  • • •     
Haematology /Renal Function   •    •  • • • •     
Biochemistry/glucose   •    •  • • • •     
Serology   •        •   • • 
PCR      •    •     
QoL questionnaire s (IVI and EQ5D -5L)  •            • 
Visual acuity6 • • • •  • • • • • • • • • 
Contrast sensitivity  • • • •         • • 
Reading speed   • • •         • • 
Colour vision   • • •         • • 
Octopus perimetry   • • •         • • 
Full field Stimulus Testing7   • • •         • • 
Microperimetry (mesopic and 
scotopic)   • • •       •  • • 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 45 of 67 
  
Visual mobility (PAMELA  or Michigan 
maze )1  •2            • 
Ocular examination  • • • •  • • • • • • • • • 
Fundus photography   •    • • • • • • • • • 
Optical coherence tomography  • • • •  • • • • • • • • • 
Adaptive optics imaging3  • •           • 
Fundus autofluorescence   •           • • 
Flash electroretinography4 • •         •  • • 
Pattern electroretinography4 • •         •  • • 
Multifocal electroretinography4 • •         •  • • 
1 A 6-week window period is permitted around the visual mobility assessments.  
2 Multiple baseline PAMELA assessments may be performed on the same day if considered logistically and clinically appropriate  
3 Adaptive optics imaging baseline assessments may be performed on the same day where considered logistically and clinically appropriate  
4 Additional baseline assessments are permitted if there is inconsistency between the screening and first baseline assessment  
5Measurements for vital signs include: blood pressure, pulse, respiration rate, arterial oxygen saturation, temperature, heigh t and weight  
6 Visual acuity at day 1 and 3 will be assessed by using the previous refraction . 
7 FST test results will be collected  retrospectively  (with written consent) for paediatric participants if the assessment has been performed 
previously   
ERG assessments may be performed under general anaesthesia if considered appropriate  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 46 of 67 
  
5.6.1  Early Stopping of Follow -up 
If a participant chooses to withdraw from the  trial, they should continue to be followed up as closely as 
possible to the follow -up schedul e defined in the protocol , providing they are willing . If, however , the 
participant exercises the view that they no longer wish to be followed up either, this view must be 
respected. Data already collected will be kept and included in analyses according to  the intention -to-
treat principle for all participants who stop follow up early.  
Participants who stop trial follow -up early may be replaced.  
5.6.2 Loss to Follow -up 
This is a highly motivated patient group who are likely to remain committed to the research. Continued 
follow up of all participants will be strongly encouraged whilst being mindful of the importance of 
ensuring the autonomy of participants in regards to their treatment decisions and willingness to 
continue to participate in the trial.  
5.6.3 Trial Closure  
The end of the entire trial is considered the last follow -up visit of the last participant . For each 
participant , the trial will terminat e at the last scheduled visit 6  months following ATIMP administration.  
The MHRA will be notified of the end of the trial within 90 days of its completion.  
5.6.4 Passive/Long Term Follow -Up After the End of the Trial  
At the end of this trial, p articipants will be invited to enrol in a 5 -year follow -up study to determine 
longe r term safety and efficacy.  
5.7 Sample Size  
This is a Phase I/II trial to establish safety and assess indicators of potential efficacy of the ATIMP, 
therefore there is no formal sample size calculation. The trial will enrol up to 27 participants (up to 18 in 
the dose escalation phase and a further 9 in the confirmatory phase), as described in section 4.3.2.2. The 
limited number of participants is necessitated by the rare nature of the disease under investigation. We 
estimate that inclusion of up to 27 participants will be sufficient to determine the safety and tolerability 
of the intervention.  
5.8 Recruitment and Retention  
5.8.1  Recruitment  
Most participants will be recruited through Moorfields Eye Hospital or the Kellogg Eye Center , or on 
referral by ophth almologists within or outside the UK or the US . Members of their direct clinical care 
team will approach potential participants in the first instance to discuss whether they would like to 
consider participating. Alternatively, potential participants may co ntact the trial  team independently.  
We expect to recruit up to 27  participants within a period of 36 months.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 47 of 67 
  
5.8.2  Retention  
Participants  will be supported to remain in follow -up by regular contact as per the protocol, provision of 
a 24-hour hotline to a member of the trial team  
5.9 Assignment of Intervention  
5.9.1  Allocation  
All participants will receive the same intervention  in this open label, non -randomised trial:  subretinal 
administration of AAV2/5 -OPTIRPE65 . The dose received by each participant will  depend on the 
time/order of their enrolment in the trial, and the extent to which dose -limiting events observed in 
earlier participants during the dose -escalation phase (See Section s 4.3.2 and 5 .4.4 for dose escalation 
information ). Children will not be e nrolled in the trial until the safety profile and recommended dose 
have been established in adults.  
5.10 Data Collection, Management and Analysis  
5.10.1  Data Collection , Management and Entry  
Syne qua non will be responsible for data management activities for the study.  
Data will be captured in a fully validated, 21 CFR Part 11 compliant Electronic Data Capture (EDC) system 
provided by Syne qua non.   
Syne qua non will grant authorised site staff with access to the EDC system following system training and 
a successful competency assessment.   
Data required by the protocol will first be recorded on source documents (e.g. medical records and 
study -specific data capture tools as needed) and then entered by site staff into the EDC system.  All 
information in EDC  must be traceable to these source documents.  Any data recorded directly into EDC 
will be defined prior to the start of data collection. All data is currently anticipated to be associated with 
source data records.  
Data validation checks will be activated during data entry to identify data discrepancies. Appropriate 
error messages will be displayed to allow modification or verification of data by the site staff.  
Monitoring staff will review the data for completeness and accuracy, instructing site staff to m ake any 
required corrections or additions via data queries.  Syne qua non will run further automated validation 
checks and review the data, raising further data queries to the sites for resolution of any inconsistencies.  
The Investigator will review the eC RFs for completeness and accuracy then electronically approve the 
data, retaining full responsibility for its accuracy and authenticity.  
Medical history and adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) termin ology.  Prior and concomitant medication will be coded using the World Health 
Organization Drug (WHO) -Drug Dictionary  which employs the Anatomical Therapeutic Chemical (ATC) 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 48 of 67 
  
classification system.  Further coding details and data management processes will be described in a Data 
Management Plan (DMP).   
All actions within the EDC system are captured within an audit trail.  After all data have been entered, 
validated and signed off, the database will be locked.  
At the end of the study, PDF copies of the eCRFs  for each subject and supporting information will be 
provided to sites and the Sponsor.  The electronic data will be provided to the Sponsor.  
5.10.3  Non -Adherence and Non -Retention  
Participants who withdraw from the trial after the intervention will be enc ouraged to participate in any 
of the planned follow -up scheduled for the trial with their consent, and data from these subjects 
collected prior to withdrawal may be included in the interpretation of results.  
Reasons for withdrawal from the trial will be d ocumented on a withdrawal CRF where possible, in 
addition to the procedures and CRF for the final visit ( 6 month) assessments with the participant’s 
consent .  
5.10.4  Statistical Methods  
5.10.4.1  Statistical Analysis Plan  
A formal statistical analysis plan will be written  by the trial sponsor and approved by the IDMC . This trial 
is an open label, no crossover, Phase I/II trial involving a small number of participants , and analysis of 
the primary and secondary outcomes will be descriptive in nature.  
5.10.4.2  Statistical Methods – Primary Outcome Analysis  
The primary outcome is safety of subretinal administration of the ATIMP, defined as  any of the below 
occurring during the 9  weeks following administration, at least possibly related to the ATIMP, not 
surgery alone:  
• Reduction in visual acuity by 15 ETDRS letters or more  
• Severe unresponsive inflammation  
• Infective endophthalmitis  
• Ocular malignancy  
• Grade III or above non -ocular SUSAR  (See Section 5.11 ). 
The number of DLEs at each dose level will be summarised by cohort and overall.  
It is anticipated that the vector will be administered at the MTD in up to 15 participants (6 adults in the 
dose escalation phase and up to 9 further adults and children in the confirmatory safety phase). Safety 
data relating to these p articipants will allow estimation of an upper bound for the true event rate 
through a 95% confidence interval.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 49 of 67 
  
5.10.4.3  Statistical Methods - Secondary Outcome Analysis  
The secondary outcomes are measures of the efficacy of the ATIMP; these will be perform ed on an 
individual participant basis and will be primarily descriptive in nature. Standard assessments will be used 
to measure visual function and established methods of analysis, appropriate for the assessment will be 
used to evaluate the data. For speci alist assessments, data will be analysed by the expert team 
member(s) who developed the assessment. F inal data will be reported descriptively.  
Efficacy will be indicated by:  
1) Any improvement in visual function from baseline that is greater that the test -retest variation for that 
test and is sustained for at least two consecutive assessments.  
2) Any improvement in retinal function from pre -intervention  assessment  that is greater than the test-
retest variation and measurable by electroretinography (ERG)  
If no ERG was previously detectable, then the presence of any reproducible response with appropriate 
waveform would be clinically significant. If an ERG was there to start with, any of the following would be 
significant:  
• an improvement in amplitude of >50  % in DA 0.01 b -wave (rod system sensitivity);  
• bright flash DA 10 a-  wave (photoreceptor improvement);  
• the 30Hz flicker; and  
• the LA 3.0 photopic a - and b -waves.  
In terms of timing: > 3ms improvement in photopic parameters and bright flash DA 10 a -wave;  6ms for 
the DA 0.01 and DA 10.0 b -waves.  
Measures will be reported individually and aggregated across participants as the proportion who satisfy 
the above criteria.  
Quality of life patient reported outcome measures will be used to correlate a participant ’s feeling about 
their own wellbeing with clinical observations.  
Any deviations from the original statistical plan will be approved by the CM T and IDMC  and described in 
the final report, as appropriate.  
5.10.4.4  Statistical Methods – Health Economic Analys is 
No health economic evaluation is planned, but the collection of EQ5D would allow QALYs to be 
calculated.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 50 of 67 
  
5.11 Data Monitoring  
5.11.1  Independent Data Monitoring  Committee  (IDMC)  
To ensure the safety and efficacy and overall trial conduct, an IDMC will be established and take part in 
the data monitoring. The IDMC will consist of members with specific expertise in ophthalmology and 
mole cular genetics.  The IDMC will make recommendations on the safety data prior to any dose change, 
and prior to the first pa rticipant aged under 1 6 being included  in the trial.  
Further details of the roles and responsibilities of the  IDMC , including membership, relationships with 
other committees, decision making processes, and the timing and frequency of interim analyses (and  
description of stopping rules and/or guidelines where applicable) are described in detail in the  Gene 
Therapy Trial for LCA OPTIRPE65  IDMC charter.  
5.11.2  Interim Analyses  
No formal interim analysis is planned within the trial, but periodic reports concerning participant safety 
and key efficacy outcomes will be prepared for the IDMC as agreed in the Terms of Reference.    
5.11.3  Data Monitoring for Harm  
5.11.3.1  Safety reporting  
EMAS Pharma will be responsible for pharmacovigilance services.  
Definitions o f harm of the EU Directive 2001/20/EC Article 2 based on the principles of ICH GCP apply to 
this trial.  
Table 3: Adverse Event Definitions  
Adverse Event (AE)  Any untoward medical occurrence in a clinical trial participant 
administered  a medicinal product and which does not 
necessarily have a causal relationship with this product.  
Adverse Reaction (AR)  Any untoward and unintended response to an investigational 
medicinal product related to any dose administered  
This includes medication errors, uses outside of protocol 
(including misuse and abuse of product)  
Unexpected Adverse Reaction 
(UAR)  An adverse reaction, the nature or severity of which is not 
consistent with the applicable product information ( e.g. 
Investigator’s Brochure for an unauthorised product or summary 
of product characteristics  (SPC)  for an authorised product.  
Serious Adverse Event (SAE) or 
Serious Adverse Reaction (SAR)  Any AE or AR that at any dose:  
• results in death  
• is life threatening*  
• requires hospitalisation or prolongs existing 
hospit alisation ** 
• results in persistent or significant disability or incapacity  
• is a congenital anomaly or birth defect  
• or is another important medical condition *** 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 51 of 67 
  
  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
*the term life threatening here refers to an event in which the participant  is at risk of death  at the 
time of the event; it does not refer to an event that might hypothetically cause death if it was more 
severe ( e.g. a silent myocardial infarction)  
** Hos pitalisation is defined as an in -patient admission, regardless of length of stay, even if the 
hospitalisation is a precautionary measure for continu ed observation. Hospitalisation  for pre -existing 
conditions (including elective procedures that have not wor sened) do not constitute an SAE  
*** Medical judgement should be exercised in deciding whether an AE or AR is serious in other 
situations. Important AEs or ARs that may not be immediately life threatening or result in death or 
hospitalisation, but  may seriously jeopardise the participant by requiring intervention to prevent 1  of 
the other outcomes listed in the table ( e.g. a secondary malignancy, an allergic bronchospasm 
requiring intensive emergency treatment, seizures or blood dyscrasias that do not require 
hospitalisation, or development of drug dependency).  
 
Adverse events include:  
• an exacerbation of a pre -existing illness  
• an increase in the frequency or intensity of a pre -existing episodic event or condition  
• a condition (regardless of whether PRESENT prior to the start of the trial) that is DETECTED after 
trial drug administration . (This does not include pre -existing conditions recorded as such at 
baseline – as they are not detected after trial drug administration)  
• continuous persistent disease  or a symptom present at baseline that worsens following ATIMP 
administration  
Adverse events do NOT include:  
• Medical or surgical procedures: the condition that leads to the procedure is the adverse event  
• Pre-existing disease or a condition present before A TIMP administration  that does not worsen  
• Hospitalisation where no untoward or unintended response has occurred e.g.  elective cosmetic 
surgery  
• Overdose of medication without signs or symptoms  
5.11.3.2 Other Notifiable Adverse Events  
In order to manage the s afety risks associated with administration of the vector, all safety events will be 
reviewed within a short time frame for all participants , as described in the OPTIRPE65  Data 
Management Plan. Pregnancy is the only additional notifiable event that requires  expedited reporting.  
 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 52 of 67 
  
5.11.3. 3 Procedures to follow in the event of female participants becoming 
pregnant  
A pregnancy test will be conducted for all females of child bearing age and the results will be recorded in 
the medical notes before enrolling a volunteer  to the trial. Females with a positive pregnancy test at this 
point will be excluded from the trial.  
A further pregnancy test will be performed on the day of administration of the ATIMP. Female 
participants with a positive pregnancy test at this point will be excluded from the trial prior to 
administration of the ATIMP.  
Although participants are instructed to use double barrier contraception, we cannot exclude entirely 
that a participant  might become pregnant after administration of the ATIMP. In  the unlikely event that a 
participant  is found to be pregnant we will notify the ir GP that she is participating in a gene therapy trial 
and that, although the risks involved are minimal, there is a chance of gene transfer to the unborn child. 
With the par ticipant ’s consent, we will ask the GP/obstetrician to provide us with regular reports about 
the pregnancy until delivery. The pregnancy will be reported to EMAS Pharma  within 24 hours of the 
investigator becoming aware of the event. We will continue follo w-up of the participant until outcome 
of the pregnancy. However, if the participant  is unable or unwilling to participate further in the trial, she 
will be encouraged to continue clinical monitoring visits to assess ocular health. In that situation, we 
may  choose to enrol another participant  to ensure the scientific validity of the trial.  
5.11.3. 4 Procedures to follow in the event of the partners of male 
participants becoming pregnant  
Although participants are instructed to use double barrier contraception,  we cannot exclude entirely 
that the partner of a participant  might become pregnant after administration of the ATIMP. In the 
unlikely event that this occurs  we will notify the participant ’s GP that he is participating in a gene 
therapy trial and that, alt hough the risks involved are minimal, there is a chance of gene transfer to the 
unborn child. With the participant ’s consent, we will contact the partner to ascertain the status of the 
pregnancy and the outcome. The pregnancy will be reported to EMAS  Pharm a 
5.11.3. 5 Investigator responsibilities relating to safety reporting  
The Investigator will assume overall responsibility for evaluating and reporting adverse events. In urgent 
situations a member of the trial team may report  on their  behalf, while making every effort to discuss 
the event with them . All non -serious AEs and A Rs including all events observed following ATIMP 
administration, whether expected or not, should be recorded in the participant’s medical notes and  in 
the eCRF . The se should be entered on to the database according to the timelines defined in the Gene 
Therapy for LCA OPTIRPE65  Data Management Plan to allow appropriate monitoring by the CMT . SAEs 
and SARs should be notified to EMAS Pharma  within 24 hours of the investi gator becoming aware of the 
event.  
Clinically significant abnormalities in the results of objective tests will also be recorded as adverse 
events. If the results are not exp ected as part of disease or surgery these will also be recorded as 
unexpected. Ther e are currently no expected events associated with the ATIMP.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 53 of 67 
  
All serious adverse events will be recorded in the hospital notes and the CRF . Adverse events will be 
recorded with clinical symptoms and accompanied with a simple, brief description of the even t, 
including dates as appropriate. All adverse events will be recorded until the end of the trial (refer to 
Section  5.6.3 for definition) , or until pregnancy outcome in the case of pregnancy . All SAEs will be 
recorded, fully investigated and appropriately managed until resolution or stabilisation  and CI sign off.  
5.11.3. 5.1 Seriousness assessment  
When an AE or AR occurs, the investigator responsible for the care of the participant must first assess 
whether or not  the event is serious using the definition given in T able 3. If the event is classified as 
‘serious’ an SAE form must be completed and emailed to EMAS Pharma, notified within 24-hours of the 
investigator becoming aware of the event.  
5.11.3. 5.2 Severity or grading of Adverse Events  
The severity of all AEs and/or ARs (serious and non -serious) in this trial should be graded using the 
toxicity grading in NIH CTCAE Version 4.0  (NIH , 2009 ). 
Table 4: Grading of Adverse Events  
Category  Definition  
Mild  (Grade I)  
  Asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated  
Moderate  (Grade II)  Minimal, local or non -invasive intervention indicated; limiting 
age appropriate instrumental ADL*  
Severe  (Grade III)  Severe or medically significant but not immediately life 
threatening; hospitalisation or prolongation of hospitalisation 
indicated; disabling; limiting self -care ADL**  
Grade IV  Life threatening consequences; urgent intervention indicated  
Grade V  Death related to A E 
* Instrumental ADL (Activities of Daily Living) refer to preparing meals, shopping for groceries or clothes, 
using the telephone, managing money , etc 
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medic ations, and not bedridden.  
5.11.3. 5.3 Causality  
Causality will be assessed in terms of both the ATIMP and the surgical procedures. Based on all available 
information at the time of completion of the case report form, t he investigator must assess the causal ity 
of all serious events or reactions . It is of particular importance in this trial to capture and differentiate 
events related to:  
• The ATIMP administration surgery  
• The ATIMP  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 54 of 67 
  
The differentiated causality assessments will be captured in the trial specific CRF and SAE form using the 
definitions in Table  5.  
Table 5: Causality definitions  
Relationship  Description  Event Type  
Unrelated  There is no evidence of any causal relationship  Unrelated SAE  
Unlikely to be related  There is little evidence to suggest that there is a causal 
relationship ( e.g. the event did not occur within a reasonable 
time after administration of the trial medication). There is 
another reasonable explanation for the event ( e.g. the 
participant’s clinical condition or other concomitant treatment)  Unrelated SAE  
Possibly relate d There is some evidence to suggest a causal relationship ( e.g. 
because the event occurs within a reasonable time after 
administration of the trial medication). However, the influence 
of other factors may have contributed to the event ( e.g. the 
participant ’s clinical condition or other concomitant treatment)  SAR 
Probably related  There is evidence to suggest a causal relationship and the 
influence of other factors is unlikely  SAR 
Definitely related  There is clear evidence to suggest a causal relationship and 
other possible contributing factors can be ruled out.  SAR 
 
 
5.11.3. 5.4 Expectedness  
In view of the very limited clinical experience with the ATIMP there are at present no events considered 
as expected for the ATIMP. Therefore, any SAEs that are related to the ATIMP ( i.e., considered a SAR) 
will be deemed a SUSAR (suspected, unexpected, serious adverse reaction) and MHRA, REC/IBC, FDA, 
and NIH reporting guidelines apply (see Notifications sections of the protocol).  
Table 6: Assessment of expectedn ess  
Category  Definition  
Expected  
  An adverse event that is classed in nature as serious and which 
is consistent with the information about the surgery  listed in the 
Investigator Brochure  or clearly defined in the protocol. In view 
of the very limited clinical experience with the ATIMP there are 
at present no events considered as expected for the ATIMP 
listed in the current Investigator Brochure.  
Unexpected  An adverse event that is classed in nature as serious and which 
is not consiste nt with the information about the  ATIMP  and 
surgery  listed in the Investigator Brochure *or clearly defined in 
the protocol.  
*This includes listed events that are more frequently reported or more severe than previously reported  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 55 of 67 
  
The reference document to be used to assess expectedness against the ATIMP  and surgery  is the 
Investigator Brochure.  Procedure -related adverse events cannot be considered expected  to the ATIMP . 
Previous experience with AAV -mediate d gene therapy in the retina indicates that the risks are largely 
limited to the eye. A temporary and/or mild decrease in visual acuity, due to detachment of the retina 
or post -surgical inflammation, is to be expected after intraocular surgery and will not  cause undue 
discomfort to the participants.  Therefore, we have defined the success criteria for the primary outcome 
(safety) as the absence of an adverse event that has a substantial and sustained negative impact on 
vision, as well as the absence of any n on-ocular SUSAR.  
Expected events associated with surgery:  
• Temporary and/or mild decrease in visual acuity, due to detachment of the retina or post -
surgical inflammation  
• Ocular discomfort  
• Epiphora  
• Periocular swelling  
• Diplopia  
• Ptosis  
• Subconjunctival or intraocular haemorrhage  
• Corneal abrasion  
• Retinal tear or detachment  
• Wound leak  
• Ocular hypotony or raised intraocular pressure  
• Overfill or underfill of any intraocular gas tamponade  
• Mild intra-  or extra- ocular inflammation  
• Scleral or conjunctival suture granuloma  
• Lens opacity or dislocation  
• Systemic adverse events related to sedation or general anaesthes ia, including nerve or vascular 
injury  
5.11.3. 6 Notifications  
5.11.3. 6.1 Notifications by the Investigator  to EMAS 
All adverse events will be recorded in the hospital notes and the CR F from the date of written informed 
consent  until last study visit.   Investigators should notify EMAS of any SAEs occur s during this period.    
After last visit, any SAE reported to the investigator and considered causally related to trial treatment 
should be reported as part of the follow up study . For any participants that do not go into the follow up 
study, then SAEs that occur after the end of  the trial and that may be attributed to ATIMP 
administration should be reported to the relevant regulatory agencies .  
 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 56 of 67 
  
EMAS must be notified of all SAEs and SUSARs within 24 hours  of the investigator becoming aware of 
the event.  The investigator will resp ond to any SAE queries raised by the sponsor as soon as possible.  
The SAE form must be completed by the investigator (the consultant named on the delegation of 
responsibilities list who is responsible for the participant’s care ) with attention paid to the  grading, 
causality and expectedness of the event. In the absence of the responsible investigator, the SAE form 
should be completed and signed by a member of the site trial team and emailed as appropriate within 
the timeline. The responsible investigator s hould check the SAE form at the earliest opportunity, make 
any changes necessary, sign and then email to EMAS . Detailed written reports should be completed as 
appropriate.  Systems will be in place at the site to enable the investigator to check the form fo r clinical 
accuracy as soon as possible.  
The minimum criteria required for reporting an SAE are the trial number and date of birth, name of 
reporting investigator and sufficient information on the event to confirm seriousness.  Any further 
information regarding the event that is unavailable at the time of the first report should be sent as soon 
as it becomes available.  
The SAE form must be scanned and sent by email to the trial team on drug.safety@emaspharma. com  
Participants must be followed up until clinical recovery is complete and laboratory results have returned 
to normal or baseline values, or until the event has stabilised. Follow -up should continue after 
completion of trial follow -up (i.e. 6  months after delivery of ATIMP) if necessary. Follow -up SAE forms 
(clearly marked as follow -up) should be completed and emailed to EMAS as further information  
becomes available . Additional information and/or copies of test results may be provided separate ly. The 
participant must be identified by trial number  and date  of birth only. The participant’s name should not 
be used on any correspondence and must be blacked out and replaced with trial identifiers on any test 
results  if the name is shown.  
5.11.3. 6.2  Repor ting Urgent Safety Measures  
The sponsor  or investigator may take appropriate urgent safety measures in order to protect research 
participants against any immediate hazard to their health or safety.  
If any urgent safety measures are take n, MeiraGTx UK  II Ltd . shall immediately (no later than 3 days 
from the date the measures are taken), give written notice to the MHRA, the relevant REC and the 
Sponsor of the measures taken and the circumstances giving rise to those measures.  
5.11.3. 6.3 EMAS responsibil ities  
EMAS will follow EMAS Standard Operating Procedures and a study specific Safety Management Plan to 
ensure that case processing of events occurs within appropriate regulatory timeframes. EMAS will 
submit Development Safety Update Reports (DSURs) to regulatory authorities.  
5.11.3. 6.4 Reporting SUSARs in International Trials  
The mechanism for reporting SUSARs that occur outside  of the UK to the MHRA, and those that occur 
outside of the US to the FDA will be covered in the trial specific  Safety Management  Plan . 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 57 of 67 
  
5.11.3. 6.5 Annual Progress Reports  
An annual progress report (APR) will be submitted to the REC within 30 days of the anniversary date on 
which the favourable opinion was given, and annual ly until the trial is declared ended.  Annual IRB 
applications  for continuing review will be submitted with sufficient time to allow review and approval of 
trial continuation.  
5.11.4  Quality Assurance and Control  
5.11.4.1  Risk Assessment  
The Quality Assurance  (QA) and Quality Control  (QC) considerations for the  Gene  Therapy for LCA 
OPTIRPE65  trial are based on the M eiraGTx UK II Ltd . Quality Management Policy that includes a formal 
Risk Assessment, and that acknowledges the risks associated  with the conduct of the trial and proposals 
of how to mitigate them through a ppropriate QA and QC processes. Risks are defined in terms of their 
impact on: the rights and safety of participants; project concept including trial design, reliability of 
results and institutional risk; project manage ment; and other considerations.  
5.11. 4.2 Clinical Monitoring  
The frequency, type and intensity of routine and triggered on -site monitoring will be detailed in the trial 
Monitoring Plan (MP). The MP will also detail the procedures for review and sign -off of monitoring 
reports. In the event of a request for a trial site inspection by any regulatory authority MeiraGTx UK II 
Ltd. must be notified as soon as possible.  
5.11.4.3.1  Direct access to participant records  
Participating investigators must agree to allow trial related monitoring, including audits , REC /IRB  review  
and regulatory inspections, by providing access to source data and other trial related documentation as 
required. Participant consent for this will be obtained as part of the informed consent process for the 
trial.  
5.11.4.4  Trial Ove rsight  
Trial oversight is intended to preserve the integrity of the trial by independently verifying a variety of 
processes and prompting corrective action where necessary. The process es reviewed relate to 
participant enrolment, consent, eligibility, and allocation to trial  groups; adherence to trial interventions 
and policies to protect participants, including reporting of harms; completeness, accuracy and timeliness 
of data collection; and will verify adherence to applicable policies detailed in the Compliance section of 
the protocol.  
In multi -centre trials this oversight is considered and described both overall and for each recruiting 
centre by exploring the trial dataset or performing site visits as described in the  Monitoring Plan.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 58 of 67 
  
5.11.4.4.1  Clinical Management Team  
A Clinical Management Team (CMT ) will be set up to assist with developing the design, co -ordination  
and strategic management of the trial. The membership, frequency of m eetings, activity (including trial 
conduct and data review) and authorit y will be covered  in the CMT terms of reference.  
5.11.4.4.2  Independent Data Monitoring Committee  
The IDMC is responsible for safeguarding the interests of trial participants, monitoring the accumulating 
data and making recommendations to the CMT  on whethe r the trial should continue as planned. The 
membership, frequency of meetings, activity (including review of trial conduct and data) and authority 
will be covered in the IDMC terms of reference.  The IDMC will consider data in accordance with the 
statistical analysis plan and w ill advise the CM T through its C hair.  
5.11.4.4. 3 Trial  Sponsor  
The role of the sponsor is to  undertake regulatory  responsibilit ies, and to  secur e arrangements to 
initiate, manage and finance the  trial. MeiraGTx UK II Ltd . is the trial sponsor . 
6 Ethics and Dissemination  
6.1 Research Ethics Approval  
Before initiation of the trial at any clinical site, the protocol, all informed consent forms and any material  
to be given to the prospective participant will be submitted to the relevant REC /IRB  for approval. Any 
subsequent amendments to these documents will be submitted for further approval. Before initiation of 
the trial at each additional  clinical site, the same/amended documents will be submitted for local 
approval. An annual progress rep ort or application for annual Continuing Review will be submitted to 
the relevant REC/IRB at each clinical trial site.  
The rights of the participant to refuse to participate in the trial without giving a reason must be 
respected. After the participant,  has entered the trial, the clinician  remain s free to give alternative 
treatment to that specified in the proto col, at any stage, if the clinician  feels it to be in the best interest 
of the participant. The reasons for doing so must be recorded. The participant remain s free to change 
their mind at any time about the ATIMP administration (before administration)  and follow -up (at any 
time)  without giving a reason and without prejudicing their further treatment.  
6.2 Competent Authority Approvals  
This protocol will be submitted to the national competent or equivalent authority ( i.e. MHRA in the UK 
and Food and Drug Administration ( FDA)  in the US ). 
This is  a Clinical Trial of an Investigational Medicinal Product (IMP) as defined by the EU Directive 
2001/20/EC. Th erefore, a CTA is required in the UK.  
This is a Clinical Trial of an Inve stigational New Drug as defined by 21CFR Part 312  of the Code of Federal 
Regulations. Therefore, an Investigational New Drug Application (IND) is required in the US.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 59 of 67 
  
This trial is a human gene transfer study and therefore in the US must be reviewed by the initial site's 
Institutional Biosafety Committee and possibly by the Recombinant DNA Advisory Committee (RAC) of 
the NIH's Office of Biotechnology Activities (OBA) . 
The progress of the trial,  safety issues and reports, including expedited reporting of SUSARs,  will be 
reported to the Competent Authority, regulatory agency or equivalent in accordance with relevant 
national and local requirements and practices.  
6.3 Other Approvals  
The p rotocol will be submitted by those delegated to do so to the local department of each participating 
site. A copy of the local approval (or other relevant approval as above) and of the P articipant 
Information Sheet (PIS)  and consent form on local headed pap er must be forwarded to MeiraGTx UK II 
Ltd. as part of the site initiation process prior to the site being designated ‘open to recruitment’ status.  
Participating sites receiving funding or support from the US government will obtain a Federal Wide 
Assurance  (FWA).  For ATIMP trials using Genetically Modified Organisms, organisations should also 
receive approval from their relevant national body to use the product ( i.e. notification to the HSE in the 
UK).  
6.4 Protocol Amendments  
MeiraGTx UK II Ltd . will be res ponsible for amendments to the protocol . MeiraGTx UK II Ltd . will be 
responsible for ensuring that  protocol amendments  are submitted to  national competent authorities, 
and to investigators at each clinical trial site.  
Investigators at each clinical site will be responsible for submitting protocol amendments to the relevant 
REC/IRBs for approval, as well as any additional competent authorities in each country that require 
notification (e.g. the NIH OBA).  
6.5 Consent or Assent  
Potential participants  will be provided with a Participant Information Sheet (PIS) and given time to read 
it fully. Following a discussion with a medically  qualified investigator or suitable trained and authorised 
delegate, any questions will be sat isfactorily answered and if the participant is willing to participate, 
written informed consent will be obtained. During the consent process it will be made completely and 
unambiguously clear that the participant (or parent or guardian of a child) is free to refuse to participate 
in all or any aspect of the trial, at any time and for any reason, without incurring any penalty or affecting 
their treatment (or that of their child).  
 
Minors who are unable to consent for themselves will not be enrolled in the tr ial without the consent of 
their parent(s) or legal guardian(s). Children or adolescents will be asked to assent or agree. A 
Participant Information and Assent sheet that describes the details of the trial, trial procedures, and 
risks in simplified form will be provided to minors who have the capacity to provide informed assent. 
Participation must be refused in the event that assent is not given. Assent forms do not substitute for 
the consent form signed by the participant ’s legally authorized representativ e.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 60 of 67 
  
 
Consent will be re -sought  if new information becomes available  that affects the participant’s consent in 
any way . This will be documented in a revision to the participant information sheet and the participant 
will be asked to sign an updated consent f orm. These will be approved by the appropriate ethics 
committee prior to their use. Consent will also be re -sought in t he event that a child’s carer changes.  
A copy of the approved consent form is available from MeiraGTx UK II Ltd .  
6.6 Confidentiality  
All data will be handled in accordance with the UK Data Protection Act 1998  and 2018  or the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA).  
These regulations require a signed subject authorization informing the participants of the following:  
• What protected health information (PHI) will be collected from participants in this trial  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a participant revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to u se all information collected prior to the revocation of subject 
authorization.  For participants that have revoked authorization to collect or use PHI, attempts should 
be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of 
their scheduled trial period.  
Participant confidentiality will be held strictly in trust by the investigators, trial  staff, and the sponsor 
and their age nts, to the extent provided by F ederal, state, and local law.  This confidentialit y is extended 
to cover testing of biological samples and genetic tests in addition to any trial information relating to 
participants. All laboratory specimens, evaluation forms, reports, and other records that leave the site 
will be identified only by a co ded number in order to maintain subject confidentiality.  All records will be 
kept locked and all computer entry and networking programs will use coded numbers only . Participants 
will not be identified in any publicly released reports of this trial.  
Acces s to trial records will be limited to the minimum number of individuals necessary for quality 
control, audit and analysis.  Clinical information will not be released without written permission of the 
subject, except as necessary for trial -related monitoring , audits, REC/ IRB review, and regulatory 
inspections by University or government entities. In such  cases , the clinical trial site will provide direct 
access to all source data, documents, and records maintained by the investigator, including but not 
limite d to, medical records (office, clinic, or hospital) for the trial participants. Trial participants will be 
informed of this during the informed consent process.  
No information concerning the trial  or the data will be released to any unauthorized third par ty without 
prior written approval of the MeiraGTx UK II Ltd.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 61 of 67 
  
The Case Report Forms (CRFs) will not bear the subject’s name or other personal identifiable data. The 
date of birth and participant  identification number, w ill be used for identification.  
6.7 Declaration of Interests  
The trial is funded by MeiraGTx  UK II  Ltd. 
James Bainbridge declares a financial interest in the company and  receipt of payment for consultancy 
services.  
Michel Michaelides declares a financial interest in the company and  receipt o f payment for consultancy 
services.  
6.8 Indemnity  
MeiraGTx UK II Ltd . holds insurance to cover participants for injury caused by their participation in the 
clinical trial. Participants may be able to claim compensation if they can prove that MeiraGTx UK II  Ltd. 
has been negligent. However, as this clinical trial is being carried out in a hospital, the hospital continues 
to have a duty of care to the participant in  the clinical trial. MeiraGTx UK II Ltd . does not accept liability 
for any breach in the hospit al’s duty of care, or any negligence on the part of hospital employees. This 
applies whether the hospital is an NHS Trust or not.  This does not affect the participant’s right to seek 
compensation via the non -negligence route.  
 
Participants may also be ab le to claim compensation for injury caused by participation in this clinical trial 
without the need to prove negligence on the part of MeiraGTx UK II Ltd . or another party.  Participants 
who sustain injury and wish to make a claim for compensation should d o so in writing in the first instance 
to the Chief Investigator, who will pass the claim to MeiraGTx UK II Ltd.’s  insurers , via the Sponsor’s office.  
 
Hospitals selected to participate in this clinical trial shall provide clinical negligence insurance cover for 
harm caused by their employees and a copy of the relevant insurance policy or summary shall be provided 
to MeiraGTx UK II Ltd ., upon request.  
6.9 Finance  
The Gene Therapy Trial for LCA OPTIRPE65  is funded by Medical Research Council grant number 
MR/M015815/1 and by MeiraGTx  UKII Ltd. It is not expected that any further funding will be sought.  
6.10 Archiving  
6.10.1  Archiving of Essential Trial D ocumentation Relating to 
Traceability  
Requirements for a traceability system and document archiving will be met in line with Regulation 
1394/2007 on Advanced Therapy Medicinal Products and the applicable Directives therein. To comply 
with the regulatory re quirements, each responsible party (the sponsor of the trial, the manufacturer a nd 
the investigator(s)/institution(s) where the ATIMP is used) will ensure that the information relating to 
the traceability and accountability, from the production of ATIMPs t o the recipient ( participant ) 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 62 of 67 
  
receiving the ATIMPs, are archived for a minimum of 30 years  after the expiry date of the ATIMP. These 
requirements will be set out in contractual agreements between the parties and the sponsor.  
The following essential docume nts/traceability data will be retained by the investigator and institution 
responsible for the human application of the ATIMP:  
• Shipping Records for the ATIMP  
• Certificate of Analysis of the ATIMP  
• Subject identification code list  
• ATIMP accountability at th e site including final disposition of both used and unused product  
These records contain relevant information for traceability purposes and at least the following minimum 
data set from these records should be kept for 30 years after the expiry date of the product, or longer if 
required by the terms of the clinical trial authorisation or by the agreement with the sponsor:  
• Identification of the investigator/institution  
• Identification of the sponsor  
• Identification of the manufacturing site  
• Product name/code   
• Pharmaceutical form, route of administration, quantity of dosage units and strength  
• Batch number  
• Trial refe rence code  
• Trial Participant  code  
• Participant  identification code list (links name of recipient to the trial participant code)  
• Product expiry/ retest date  
• Date of administration  
• Participant medical record should also contain the product name /code , the trial reference code, 
trial particip ant code and administration dates and doses  
• Records of any product that was unused or destroyed at site and its final status  
6.10.2  Archiving of Other Essential Trial Documentation  
Trial documents should be retained for a minimum of 2 years after an FDA marketing application is 
approved for the ATIMP and until there are no pending or contemplated marketing applications for the 
ATIMP, or if an application is not approved for the ATIMP, until 2 years after shipment and delivery of 
the drug for investigational use has been discontinued and FDA is notified. For gene therapy tria ls, 
current F ederal and State of Michig an requirements state that research records should be kept 
indefinitely, until further notice. Archiving of REC/IRB notices should be maintained according to local 
and/ or institutional requirements.  
Essential documents are those which enable both the cond uct of the trial and the quality of the data 
produced to be evaluated and show whether the site complied with the principles of Good Clinical 
Practice and all applicable regulatory requirements.  
MeiraGTx UK II Ltd . will notify sites when trial documentation can be archived,  and which documents 
must be archived for the 30 -year period. All archived documents must continue to be available for 
inspection by appropriate authorities upon request.  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 63 of 67 
  
Destruction of essential documents will require authorisation from the Sponsor.  
6.11 Access to Data  
The investigators/ institutions will permit trial- related monitoring, audits, REC review, and regulatory 
inspections, providing direct access to source data/documents. Trial participants are informed of this 
during the  informed consent discussion. Participants will consent to provide access to their medical 
notes.  
Requests for access to trial data will be considered , and approved in writing where appropriate , after 
formal application to  the CMT. Considerations for appro ving access are documented in the CM T Terms  
of Reference.  
6.12 Ancillary and Post -Trial  Care  
Participants will be invited to participate in a follow -up study after completion of this trial.  
6.13 Publication  Policy  
6.13.1 Trial Results  
All proposed scientif ic publications will be discussed with the Sponsor prior to publication. Since this is 
an exploratory , open -label, P hase I/II trial, progress and significant findings may be presented at 
scientific forums/meetings and/or published during the course of the trial.  
The results of the trial will be disseminated regardless of the direction of effect.  
7 Ancillary Studies  
There are no currently planned ancillary studies. Any future ancillary studies will be subject to separate 
funding, and will be submitted for et hical and regulatory review as appropriate.  
8 Revision  Histor y 
Protocol Version  and  Date  Reason for Amendment  
Protocol V1.1 dated 28.01.2016   Clarify safety reporting procedures as requested 
by MHRA  
Protocol V2 dated 6th June 2016  Further clarification  of safety reporting 
procedures as requested by the MHRA.  
Updated inclusion/exclusion criteria as requested 
by the US FDA.  
Enhanced description of the method of 
measuring the primary objective and outcome  
Enhanced description of the dose limiting criteria  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 64 of 67 
  
Minor modification to wording and language to 
correct typographical errors and ensure 
consistency throughout  
Change in name of funder from Athena Vision 
Ltd. to MeiraGTx UK Ltd . 
Protocol V3 dated 2nd August 2016  Visual acuity assessments at day 1 and day 3 
post -treatment had been erroneously omitted 
from V2. These were replaced.  
UCL CCTU Clinical Project Manager was replaced 
and details updated.  
Protocol V4  dated 10 February 2017  To reflect the change in sponso r from UCL to 
MeiraGTx UK II Ltd . 
Minor modification to wording and language to 
correct typographical errors and ensure 
consistency throughout  
To clarify the  DLE and safety definitions  
 
To clarify the primary objective and outcome 
measures  
To describe the outsourcing of data management, 
pharmacovigilance and clinical monitoring to 
CROs  
Protocol V 5 dated 12 April 2017  To extend the course of post -surgery 
prophylactic steroids from 4 weeks to 8 weeks. 
Consequently, the duration for considering dose 
limiting events has been extend ed from 6 weeks 
to 9 weeks to cover the period of steroid 
administration and one additional week  and 
other minor clarifications  
Protocol V6  dated 21 August 2017  To update the prophylactic steroid regime n in 
children , and clarify safety reporting and safety 
dose for children  
Protocol V7  dated 23 February 2018  To clarify the allowance of data obtained from 
the natural history study be used for screening 
and or baseline assessments (with consent from 
subjec ts) in order to avoid unnecessary testing of 
subjects.  
 
Clarify that more than 1 surgeon at a site may 
inject vector  
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 65 of 67 
  
Expand the number of categories for ATIMP 
administration surgery from related or unrelated 
to: unrelated, unlikely, possibly, probably  or 
definitely  
Protocol V8  dated 11 June 2018  To add Full field Stimulus Testing as an 
assessment for children  
9 References  
 Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce -
Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. Long- term restoration of 
rod and cone vision by single dose rAAV -mediated gene transfer to the retina in a canine model 
of childhood blindness.  Mol Ther, 2005, 12(6):1072- 82.  
Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce -Kelling SE, Anand V, 
Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J.Gene therapy restores vision in a 
canine model of childhood blindness.Nat Genet, 2001, 28(1):92 -5. 
Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R,  Balaggan K, Viswanathan A, Holder 
GE, Stockman A, Tyler N, Petersen -Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, 
Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital 
amaurosis. N Engl J Med, 2008, 358 :2231 -9. 
Bainbridge JW , Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat 
FM, Beattie SG, Gardner PJ, Feathers KL, Luong VA, Yzer S, Balaggan K, Viswanathan A, de Ravel 
TJL, Casteels I, Holder GE, Tyler N, Fitzke FW, Weleber RG, Nardini  M, Moore AT, Thompson DA, 
Petersen -Jones SM, Michaelides M, van den Born LI, Stockman A, Smith AJ, Rubin G and A li RR . 
Long- term effect of gene therapy on Leber Congenital amaurosis. N Eng J Med , 2015 , 372: 1887-
97. 
Balaggan  KS, Duran Y, Georgiadis A, Thaung C, Barker SE, Buch PK, MacNeil A, Robbie S, 
Bainbridge JW, Smith AJ, Ali RR.Absence of ocular malignant transformation after sub -retinal 
delivery of rAAV2/2 or integrating lentiviral vectors in p53 -deficient mice.Gene Ther, 2012, 
19(2):182- 8. 
Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, Mingozzi F, Hui D, Chung D, 
Rex TS, Wei Z, Qu G, Zhou S, Zeiss C, Arruda VR, Acland GM, Dell'Osso LF, High KA, Maguire AM, 
Bennett J.Reversal of blindness in animal models of leber congenital amaurosis using optimized 
AAV2 -mediated gene transfer. Mol Ther, 2008, 16(3):458 -65.  
Chan AW, Tetzlaff JM, Altman DG et al. SPIRIT 2013 Statement: Defining Protocol Items for 
Clinical Trials. Ann Intern Med ,2013; 158:200 -207. 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 66 of 67 
  
 Chan AW, Tetzlaff, Gotzsche et al. SPIRIT 2013 explanation and elaboration: guidance for 
protocols of clinical trials. BMJ ,2013; 346: e7586.  
Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, 
Windsor EA, Wilson JM, Flot te TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, 
Hauswirth WW.Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle 
of vision but with slow rod kinetics. Proc Natl A cad Sci U S A, 2008 ,105:15112 -7. 
Cideciyan AV , Jacobson  SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares 
MB, Schwartz SB, Komáromy AM, Hauswirth WW, Aguirre GD. Human retinal gene therapy for 
Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual 
improvement. P roc Natl Acad Sci U S A , 2013, 110(6):E517- 25. 
Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital 
amaurosis.  Hum Mol Genet, 2002, 11(10):1169- 76. 
Dekomien G, Epplen JT. Evaluation of the canine RPE65 gene in affected dogs  with generalized 
progressive retinal atrophy.  Mol Vis, 2003, 9:601 -5. 
Ekesten B, Gouras P, Salchow DJ. Ultraviolet and middle wavelength sensitive cone responses in 
the electroretinogram (ERG) of normal and Rpe65 - /- mice . Vision Res, 2001, 41(19):2425- 33. 
Hamel CP , Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, Redmond TM.  Molecular cloning and 
expression of RPE65, a novel retinal pigment epithelium -specific microsomal protein that is 
post -transcriptionally regulated in vitro.  J Biol Chem , 1993, 268: 15751 -15757.  
Jacobson SG , Acland GM, Aguirre GD, Aleman TS, Schwartz SB, Cideciyan AV, Zeiss CJ, 
Komaromy AM, Kaushal S, Roman AJ, Windsor EA, Sumaroka A, Pearce -Kelling SE, Conlon TJ, 
Chiodo VA, Boye SL, Flotte TR, Maguire AM, Bennett J, Hauswirth WW. Safety of recombinant 
adeno -associated virus type 2 -RPE65 vector delivered by ocular subretinal injection. Mol Ther, 
2006, 13(6):1074 -84. 
Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human 
retinal development. Surv Ophthalmol , 2004, 49(4):379- 98. 
Le Meur G , Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes -Madeira A, Provost 
N, Péréon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F. Restoration of vision in RPE65 -
deficient Briard  dogs using an AAV serotype 4 vector that specifically targets the retinal 
pigmented epithelium. Gene Ther , 2007, 14(4):292- 303.  
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, 
Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso 
L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright 
JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene trans fer 
for Leber's congenital amaurosis. N Engl J Med, 2008, 358:2240 -8. 
MGT003, Gene Therapy Trial for LCA OPTIRPE65  
MGT003, Protocol version 8.0 11 June 2018  Page 67 of 67 
  
Manno CS , Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle 
B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, W right 
JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, 
High KA, Kay MA. Successful transduction of liver in hemophilia by AAV -Factor IX and limitations 
imposed by the host immune response. Nat Med , 2006, 12(3): 342-7. 
Marlhens, F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou C, Liu SY, Harris E, Redmond TM, 
Arnaud B, Claustres M, Hamel CP.Mutations in RPE65 cause Leber's congenital amaurosis.  Nat 
Genet, 1997, 17(2):139- 41. 
NIH, Common terminology criteria for adverse events (CTCAE) Version 4.0, 2009, US Department 
of Health and Human Services; National Institutes of Health; National Cancer Institute: 
Washington DC.  
Nowrouzi A, Penaud -Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, Kalle CV, Sny der 
RO, Schmidt M. Integration Frequency and Intermolecular Recombination of rAAV Vectors in 
Non -human Primate Skeletal Muscle and Liver. Mol Ther, 2012, 20(6):1177 -86. 
Perrault I, Rozet JM, Gerber S, Ghazi I, Leowski C, Ducroq D, Souied E, Dufier JL, Munn ich A, 
Kaplan J. Leber congenital amaurosis. Mol Genet Metab , 1999, 68(2):200 -8. 
Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz  P, Ma JX, Crouch RK, Pfeifer K . 
Rpe65 is necessary for production of 11 -cis-vitamin A in the retinal visual cycle. N at Genet, 1998, 
20(4) : 344 -351. 
Stieger K, Colle MA, Dubreil L, Mendes -Madeira A, Weber M, Le Meur G, Deschamps JY, Provost 
N, Nivard D, Cherel Y, Moullier P, Rolling F. Subretinal delivery of recombinant AAV serotype 8 
vector  in dogs results in gene transfer to neurons in the brain. Mol Ther , 2008, 16(5):916 -23. 
  